

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
13 March 2003 (13.03.2003)

PCT

(10) International Publication Number
WO 03/020308 A1(51) International Patent Classification⁷: **A61K 39/12**,
C12N 15/34, 7/01, 5/10

(21) International Application Number: PCT/US02/28551

(22) International Filing Date:
5 September 2002 (05.09.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/317,239 5 September 2001 (05.09.2001) US(71) Applicant (for all designated States except US):
BIOMUNE [US/US]; 8906 Rosehill Road, Lenexa,
KS-66216 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **LEONARD, Joan, D.**
[US/US]; 26495 W. 110th Street, Olathe, KS 66061 (US).(74) Agents: **SPRATT, Gwendolyn, D. et al.**; Needle & Rosen-
berg, P.C., The Candler Building, 127 Peachtree Street,
N.E., Atlanta, GA 30303-1811 (US).(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CHICKEN ANEMIA VIRUS VACCINE FROM CELL LINE

(57) Abstract: Provided is a chicken infectious anemia virus (CIAV) vaccine, comprising live CIAV passaged in MDCC-MSB-1 (MSB-1) cells, wherein the vaccine does not cause Marek's Disease. Also provided is a CIAV vaccine comprising a CIA virus having the sequence of SEQ ID NO: 1. A method of making a CIAV vaccine is provided, comprising culturing CIAV in MSB-1 cells, and removing or killing any Marek's disease virus present in the CIAV-containing MSB-1 culture. Provided a method of immunizing a chicken against CIAV infection, comprising administering to the chicken an amount of the CIAV vaccine of the invention sufficient to induce an immune response to CIAV.

WO 03/020308 A1

5

CHICKEN ANEMIA VIRUS VACCINE FROM CELL LINE**CROSS REFERENCE TO RELATED APPLICATIONS**

10

This application claims benefit of priority from U.S. Provisional Application Serial Number 60/317,239, filed September 5, 2001, which application is hereby incorporated by reference in its entirety.

15

BACKGROUND OF THE INVENTION**FIELD OF THE INVENTION**

The invention relates generally to a vaccine for chicken infectious anemia virus, methods of making the vaccine and methods of immunization using the vaccine.

20

BACKGROUND

CIAV causes clinical and subclinical disease in chickens, and is recognized as an important avian pathogen worldwide. In young chickens, CIAV causes a transient severe anemia due to destruction of erythroblastoid cells in the bone marrow and immunodeficiency due to depletion of cortical thymocytes. The depletion of cortical thymocytes is considered to cause a transient immunodeficiency resulting in enhanced concurrent infections and to vaccination failures. The depletion of thymocytes and most likely also of erythroblastoid cells occurs via VIAC-induced apoptosis.

30

CIAV is a small virus of a unique type with a particle diameter of 23-25 nm and a genome consisting of a circular single-stranded (minus strand) DNA. This

5 DNA multiplies in infected cells via a circular double-stranded replicative intermediate. CIAV is not related to other known animal single stranded circular DNA viruses, such as porcine circovirus and psittacine beak-and-feather disease virus.

10 The major transcript from the CIAV genome is an unspliced polycistronic mRNA of about 2100 nucleotides encoding three proteins of 51.6 kDa (VP1), 24.0 kDa (VP2) and 13.6 kDa (VP3 or apoptin). All three proteins are synthesized in CIAV-infected cells.

15 To reduce the economic damage caused by CIAV infection, it is necessary to provide a cost-effective vaccine against CIAV. Prior attempts to provide a CIAV vaccine have required the passaging and propagation of CIAV in CIAV-susceptible SPF-embryos (See Vielitz and Voss, International Symposium on Infectious Bursal Disease and Chicken Infectious Anemia, Rauischholzhausen, Germany, 21-24 June 19114). Attempts to produce CIAV in cell lines has been problematic due to infection of susceptible cell lines with Marek's disease virus. Thus, a need exists for
20 a vaccine produced in cultured cells that will not cause Marek's disease.

The present invention meets the needs of this field by providing a vaccine without the disadvantages of embryo passaging and without the disadvantages of Marek's disease virus contamination.

25 SUMMARY OF THE INVENTION

In accordance with the purpose(s) of this invention, as embodied and broadly described herein, this invention, in one aspect, relates to a chicken infectious anemia virus (CIAV) vaccine, comprising live CIAV passaged in MDCC-MSB-1 (MSB-1)
30 cells, wherein the vaccine does not cause Marek's Disease.

In another aspect, the invention provides a CIAV vaccine comprising a CIA virus having the sequence of SEQ ID NO: 1.

5 In another aspect, the invention provides a method of making a CIAV vaccine, comprising culturing CIAV in MSB-1 cells, and removing or killing any Marek's disease virus present in the CIAV-containing MSB-1 culture. The method can include subjecting the CIAV-containing MSB-1 cell culture to at least 3 cycles of freezing and thawing, followed by a step of maintaining the cells for about 3 days
10 at about. Alternatively, filtration may be used, or centrifugation followed by treatment at about 37°C.

In a further aspect, the invention provides a method of immunizing a chicken against CIAV infection, comprising administering to the chicken an amount of the CIAV vaccine of the invention sufficient to induce an immune response to CIAV.

15 The invention has the advantage that it provides a CIAV vaccine that can be produced in a cell line and is free of contaminating viruses.

Additional advantages of the invention will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention. The advantages of the invention will be
20 realized and attained by means of the elements and combinations particularly pointed out in the appended claims. It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed.

25 BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate (one) several embodiment(s) of the invention and together with the description, serve to explain the principles of the invention.

30 Figure 1 shows PCR products (1=marker, 2=Del Ros, 3=Intervet CIAV embryo adapted and attenuated vaccine, 4=1:2 cells, 5= 1:2 supernatant, 6=1:10 cells, 7= 1:10 supernatant, 8= MSB-1 cells only).

5 Figure 2 shows restriction enzyme analysis with HindIII (1=marker, 2=CIAV Del Ros uncut, 3= CIAV Del Ros HindIII, 4=Intervet CIAV uncut, 5=Intervet CIAV HindIII, 6= 1:2 Intervet CIAV uncut, 7= 1:2 Intervet CIAV sample HindIII, 8= 1:10 Intervet CIAV HindIII).

10 Figure 3 shows the effect of freeze-thaw on the viability of MDV (Rispen's virus).

Figure 4 shows the effect of 37°C on the viability of MDV (Rispen's virus) after 3 freeze-thaw cycles.

15

DETAILED DESCRIPTION OF THE INVENTION

The present invention may be understood more readily by reference to the following detailed description of preferred embodiments of the invention and the
20 Examples included therein and to the Figures and their previous and following description.

As used in the specification and the appended claims, the singular forms "a," "an" and "the" include plural referents unless the context clearly dictates otherwise.

Ranges may be expressed herein as from "about" one particular value, and/or
25 to "about" another particular value. When such a range is expressed, another embodiment includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent "about" or "approximately," it will be understood that the particular value forms another embodiment. It will be further understood that the endpoints of
30 each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint.

The invention provides a chicken infectious anemia virus (CIAV) vaccine,

5 comprising live CIAV passaged in MDCC-MSB-1 (MSB-1) cells, wherein the vaccine does not cause Marek's Disease.

The CIAV vaccine of the invention does not produce gross lesions in a significant number of chicken embryos. The vaccine has been tested in embryos, and in the studies done, produces lesions in fewer than 10% of embryos. This is in
10 contrast to a different CIAV vaccine that is produced in chicken embryos, and causes significant lesions in the embryos.

The CIAV vaccine of the invention also does not produce significant anemia in chicken embryos.

The invention provides a CIAV vaccine comprising of any of the reported
15 strains (e.g., intervet strain, Cux-1 strain, Texas strain, DRP5 (Del Ros after 5 passages), CAV-15 strain, etc.). For example, invention provides a CIAV vaccine comprising a CIAV having the sequence of SEQ ID NO: 1. This is the sequence the Del Ros strain. The invention also provides a CIAV vaccine comprising any CIAV strain that is newly isolated or is a modified form of a known strain.

20 A method of making a CIAV vaccine is provided, comprising culturing CIAV in MSB-1. In addition to providing a method of making MSB-1- cultured CIAV free of Marek's disease virus (MDV) (see below and Example 1), the method can also produce CIAV to a titer of at least $10^{8.1}$. This is a higher titer than is typically obtained for this virus in MSB-1 cells. The details of one example of this
25 process are provided in Example 1. It is recognized that other methods for culturing CIAV in MSB-1 cells may be routinely developed and practiced.

The method of making a CIAV vaccine can be used with any of the reported CIAV strains (e.g., intervet strain, Cux-1 strain, Texas strain, DRP5 (Del Ros after 5 passages), CAV-15 strain, etc.). For example, the method of making a CIAV vaccine
30 can use a CIAV having the sequence of SEQ ID NO: 1. The method of making a CIAV vaccine can also use any CIAV strain that is newly isolated or is a modified

5 form of a known strain.

The method of making a CIAV vaccine can further comprise the step of separating the cultured CIAV from the MSB-1 cells, which typically contain MDV.

CIAV is secreted into the culture medium, thus allowing for a variety of steps for separating the CIAV from MSB-1 cells. For example, the method of making a

10 CIAV vaccine can comprise a step of subjecting the CIAV to at least 3 cycles of freezing and thawing. This disrupts the cells and inactivates a substantial amount of the MDV (an obligate intracellular pathogen). This step is usually followed with a step of maintaining the cells for about 3 days at about 37°C. This inactivates any remaining MDV. A further method of making the CIAV grown in MSB-1 cells free

15 of MDV can comprise the step of filtering the virus-containing MSB-1 cells through a 5 micron filter. Filtering can rupture the cells because they are fragile, and it also

removes any intact cells. Examples of these processes for removing MDV from the CIAV vaccine and for killing any MDV in the CIAV culture are provided in

Example 1 and Example 9). It is recognized that other methods for obtaining the

20 CIAV vaccine from MSB-1 cells that is free of MDV may be routinely developed

and practiced. For example, a process of centrifuging the CIAV infected MSB-1 cells to remove cells and most of the MDV, followed by cycles of freeze-thaw of the supernatant and maintenance at 37°C to kill any remaining MDV, is also effective.

Thus the methods of making the CIAV vaccine provided herein produce a vaccine

25 that does not cause Marek's disease in chickens immunized with the vaccine.

The invention provides a method of immunizing a chicken against CIAV infection, comprising administering to the chicken an amount of the CIAV vaccine

of the invention sufficient to induce an immune response to CIAV. The immune response produced is protective against infection by CIAV. Thus, the immune

30 response is also protective against clinical disease caused by CIAV infection.

Although the present CIAV vaccine is not attenuated immunized chickens (e.g., hens) do not typically get sick, because of the recognized age-resistance to this virus.

5 The immunization method of the invention extends to the progeny of an immunized hen. The immune response in the hen produces antibodies in the hen that are passed to the chick through the egg. The antibodies are at sufficient titer to be protective against infection by CIAV of the progeny of immunized hens. Thus, the present CIAV vaccine prevents clinical disease in the progeny of immunized
10 chickens by preventing CIAV infection in the chicks of immunized hens.

 In the immunization method of the invention, the vaccine is administered to chickens prior to the onset of egg production. For example, a valid time range for most if not all types of chickens is from about 4 to about 12 weeks of age. The lower time is relevant based on the age-resistance phenomenon noted with CIAV.

15 Although the exact age can differ among the different types of chickens, in the chicken strains tested resistance is present at as young as about 4 weeks of age. It is recognized that in chickens that develop resistance at an earlier age, the vaccine can successfully be administered before 4 weeks (i.e. any time after resistance develops).

 Similarly, for chicken types that develop resistance later, the vaccine can
20 successfully be administered any time after resistance develops. Since resistance to CIAV disease can be routinely determined, for example, by using the methods shown in the Examples, this parameter is routinely adjustable, such that the invention is not limited to a particular lower age limit for immunization.

 The upper time limit is relevant based on two general considerations: 1) the
25 need to immunize sufficiently in advance of the onset of egg production to allow antibody titers to develop in the immunized hen; and 2) the need to immunize sufficiently in advance of the onset of egg production to allow clearance of the CIAV from the immunized hen. The age of onset of egg production varies among the different types of chickens. Thus, while 24 weeks is the approximate time of
30 onset in the chickens tested, this parameter is not limited to that particular age, but is based on the routinely determinable age of onset for a given population of chickens.

 In terms of the development of sufficient antibody titer, this is expected to

5 vary within routinely determinable parameters from chicken to chicken. Thus, while
6 weeks prior to the onset of egg production has been determined to be sufficient in
the strains tested, the contemplated time frame encompasses any time that can be
determined to be sufficient for antibody production, including about 1, 2, 3, 4, 5, 6,
7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 23, 24 weeks (and intervening
10 days) in advance of egg production. Methods of measuring antibody titer and
determining sufficiency for protective immunization of progeny are routine and are
provided in the Examples herein.

In terms of the time needed to clear the virus prior to egg production, this is
expected to vary within routinely determinable parameters from chicken to chicken.

15 For the chickens exemplified herein, it was determined that 12 weeks prior to
egg production is sufficient to clear the virus. Because this parameter is also
routinely measured, the time frame contemplated encompasses any time sufficient to
clear the virus, including about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,
18, 19, 20, 21, 23, 24 weeks (and intervening days) in advance of egg production.
20 Methods of measuring virus titer and determining clearance of the virus are routine
and are provided in the Examples herein.

It should also be noted that the upper and lower time limits for
administration of the vaccine are not necessarily based on the egg production status,
antibody titer or virus titer of an individual chicken. Rather, it is the overall status of
25 the group (e.g., population, strain, etc.) of chickens to be immunized that is relevant.
Thus, if a sufficient percentage of individual chickens within a group are known or
are expected (e.g., based on prior knowledge of the group) to be at the appropriate
age for immunization, the immunization is considered successful.

The CIAV vaccine of the invention can be administered using any of the
30 typical methods. For example, an advantageous method is to administer the vaccine
in drinking water. The key features of the present water administered CIAV vaccine
are: 1) The CIAV is apathogenic for the host and is sufficiently invasive (at

- 5 an acceptable input) to induce an adequate level of antibody.
- 2) The CIAV was demonstrated to spread.
 - 3) The antibody induced will prevent the vertical transmission of a challenge virus.
 - 4) The maternal antibody is efficiently transferred to the progeny and is
 - 10 protective.
 - 5) The antibody will endure for an extended period of time.

The present data, strongly support the premise that the CIAV possesses these key features.

- 15 The vaccine can, alternatively, be administered by parenterally, including by injection or by aerosol spray (e.g., of any mucous membrane: nasal, pharyngeal, oral, ocular, intratracheal, cloacal, etc).

The invention provides a method of making a CIAV vaccine in an oncogenic cell line comprising subjecting the cell-cultured virus to more than one cycle of

20 freezing and thawing, followed by maintaining the cells for about 3 days at about 37°C, whereby contaminating virus from the cell line is killed. There are numerous oncogenic cell lines that have growth characteristics and other characteristics that make them advantageous for growing CIAV. However, due to the existence in some of these cell lines of contaminating viruses (e.g., the tumor virus associate with the

25 tumor from which the cell line was isolated), using them to produce a live CIAV vaccine has been problematic. The invention addresses this problem by providing methods of inactivating the contaminating virus without killing the CIAV. These methods are described in the Examples and elsewhere herein. Thus, the invention also provides a CIAV vaccine, comprising live CIAV passaged in an oncogenic cell

30 line, wherein the vaccine does not cause Marek's Disease.

Experimental

The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how the compounds, compositions, articles, devices and/or methods claimed herein are made and

5 evaluated, and are intended to be purely exemplary of the invention and are not
intended to limit the scope of what the inventors regard as their invention. Efforts
have been made to ensure accuracy with respect to numbers (e.g., amounts,
temperature, etc.), but some errors and deviations should be accounted for. Unless
10 indicated otherwise, parts are parts by weight, temperature is in °C or is at ambient
temperature, and pressure is at or near atmospheric.

EXAMPLES

EXAMPLE 1

15

STEPS IN MAKING THE CIAV VACCINE IN MSB-1 CELLS

MSB-1 cells are maintained in vials frozen in liquid nitrogen until such time they
are needed to expand into significant number for the propagation of the CIAV.

20 MSB-1 cells are planted as described in the scientific literature into various
tissue culture vessels in RPMI-1640 media supplemented with fetal calf serum. Cells
are incubated at about 41°C. These cells grow rapidly and can be frequently
expanded to maintain actively growing cells.

The vaccine is produced by adding the CIAV virus to cells that have been
25 expanded into new media such that the cell density is approximately 1 to 5×10^5
cells/ml media, and the virus input is at least about 1×10^5 TCID₅₀/ml media.

The virus-infected cells are incubated at about 41°C for 4 to 7 days. Cells are
microscopically examined for evidence of cell death as the determination of harvest
time.

30 A step must be added to the virus harvest procedure to ensure inactivation of any
residual Marek's disease virus that may be in the MSB-1 cells or that may be cell
free. A proven effective procedure is the filtering of the cells and media through a

- 5 Pall 4.5 to 5 micron cartridge to remove the MSB-1 cells followed by temperature treatment of the virus for about three days at about 37°C to ensure inactivation of cell-free Marek's disease virus. Alternatively, the virus may be frozen and thawed three times to sufficiently rupture the MSB-1 cells to release and inactivate Marek's disease virus (an obligate intracellular pathogen). Then the virus fluid is subjected
10 to a temperature treatment of about 37°C for 3 days to ensure complete inactivation of any residual Marek's disease virus.

Since the CIAV is very stable the vaccine can be supplied in a frozen form or in liquid form kept at refrigerated temperature of 2-7°C, or the virus may be freeze dried.

15

EXAMPLE 2

PCR AND RESTRICTION ANALYSIS

- 20 **Preparation of Intervet CIAV vaccine sample in MSB-1 cells.** Due to the incompatibility of the blue dye contained in the Intervet CIAV chicken embryo-adapted and attenuated vaccine sample (Intervet CIAV) and the PCR test, the sample was passed once in MSB-1 cells. MSB-1 cells were inoculated with 1:2 and 1:10
dilutions of virus, and cells were incubated for 96 hours prior to harvest. The culture
25 media still appeared blue due to the dye in the vaccine sample so the cells were separated from the supernatant by centrifugation and the cells were washed twice with PBS. Both supernatant and cells were stored at -70°C.

PCR. CIAV PCR following the protocol of the Center for Veterinary Biologics

- 30 **Laboratory (CVBL) in Ames, IA was conducted on the following samples:**

- 1) CIAV, Del Ros strain
- 2) Intervet embryo-adapted commercial CIAV vaccine (Intervet CIAV),

5 serial no. 2448003

3) MSB-1 cells of passage 1 (P1) of Intervet CIAV, passaged at a 1:2 dilution

4) Supernatant of P1 passaged at a 1:2 dilution

5) MSB-1 cells of passage 1 (P1) of Intervet CIAV passaged at a 1:10 dilution

6) Supernatant P1 passaged a 1:10 dilution

7) MSB-1 cells only

The primers are: 5' CTA/AGA/TCT/GCA/ACT/GCG/GA 3' and 5'

CCT/TGG/AAG/CGG/ATA/GTC/AT 3'

15

Restriction enzyme analysis. Part of the CVBL protocol to further verify CAV, uses restriction enzyme analysis with HindIII, which states that the PCR product is cut one time. For restriction enzyme analysis, the PCR products were cut out of the agarose gel and the DNA was purified. Then the products from the cell samples
20 were combined with the supernatant samples before cutting with HindIII.

Results. Table 1. PCR amplification and restriction enzyme analysis.

Sample	PCR	HindIII
	positive/negative	fragments
	(bp)	
CIAV, Del Ros strain	positive (419bp)	281 and 138 bp
Intervet CIAV	positive (419bp)	419 bp
1:2 dilution of P1 - cells	positive (419bp)	419bp
1:2 dilution of P1 - supernatant	positive (419bp)	
1:10 dilution of P1 - cells	positive (419bp)	419bp
1:10 dilution of P1 - supernatant	positive (419bp)	
MSB-1 cells only	Negative	N/A

5

Discussion. The primers used by CVBL were designed to the Cuxhaven-1 isolate which amplifies a 419bp region starting at nucleotide 654 and ends at nucleotide 1072 of the genomic DNA-plus strand. This region overlaps 3 ORF's of which one encodes for VP-1, capsid protein. These primers amplified the sample.

- 10 Surprisingly, the restriction enzyme that normally cuts the PCR product did not cut this sample. This means that the sample is probably CAV due to amplification by the primers, but it is different from the Del Ros (Delaware), CI-1 (Maryland), Cuxhaven-1 (Germany), and the Gifu-1 isolate (Japan). The difference in the nucleotide sequence may be just one base change at the HindIII site such that the
- 15 enzyme's recognition site has been altered. The difference may also be due to many base changes, but DNA sequencing of the PCR-product would be needed to determine the similarity between the Del Ros strain and the sample.

EXAMPLE 3

20

RESULTS OF CIAV-DR BIRD STUDIES

Pathogenicity evaluation of the CIAV, Del-Ros strain (CIAV-DR):

- 1) 2-day-old, CAV-negative SPF chicks; 20 inoculates, 10 negative controls;
- 25 10^{6.9} TCID₅₀ of CIAV-DR in 0.2 ml; per os.
- 2) The clinical and serological results were as follows:

ATTORNEY DOCKET NO. 02108.0002P1

5

<u>Treat.</u>	<u>Week p.i./%</u>			<u>Day p.i. (dpi)</u>		<u>Day p.i./</u>	
	<u>Weight</u>	<u>Reduction</u>		<u>Hemat. Val.</u>	<u>% Mort.</u>	<u>%Gross Les.</u>	<u>ELISA (total)</u>
	1	2	3	14	21	28	35
Negative	0	0	0	39	35	36 ^a	1/6 0/6
Control							
CAV	0	9	0	32	31	34	19/20 20/20
Del-Ros							

^aMean hematocrit values ^b Non-specific

14

- 5 This study demonstrated that the Del-Ros strain is of low virulence because of the fact that it had little or no impact on growth rate, anemia, mortality and gross lesions when administered to the most susceptible age, CIAV-negative chickens by a natural route (i.e., oral). However, Del-Ros strain was sufficiently invasive to induce a good antibody response (i.e., 100% ELISA positive; VN titers ranging from 1:256-10 1:1024. The gross lesions observed were restricted to hemorrhages of muscles and pale bone marrow.

Pathogenicity evaluation of 3 strains of CIAV; Del-Ros, CAV-9 and Texas:

- 1) 2-day-old, CAV-negative SPF chicks; 10 chicks per virus strain, 5 negative controls; approx. 105.7 TCID50 of virus in 0.2 ml; IA.
- 15 2) The clinical and serological results are as follows:

5

***Mean hematocrit values**

5

This study demonstrated that the Texas strain of CIAV was sufficiently virulent to be used as a challenge virus when inoculated into 1- or 2-day-old susceptible chicks by a parenteral route (e.g., intra-abdominal). The gross lesions observed included; thymic atrophy, subcutaneous and intramuscular hemorrhaging, pale bone marrow, enlarged end congested liver lobes and gangrenous dermatitis.

EXAMPLE 4

15 A STUDY CONDUCTED WITH CHICKEN INFECTIOUS ANEMIA VIRUS, DEL ROS STRAIN, BY SERIAL BACK PASSAGING IN SPF CHICKENS TO DEMONSTRATE VIRUS DOES NOT BECOME VIRULENT

20

INTRODUCTION

A host animal reversion to virulence study was conducted on the chicken infectious anemia virus, Del Ros strain (CIAV-DR) by serial backpassage in CIAV serologically negative SPF chickens.

25

PROCEDURE

The potential reversion to virulence of the CIAV-DR live vaccine by serial backpassage in the host animal was evaluated by daily observations for clinical signs, hematocrit value determinations and postmortem examinations for gross lesions characteristic of CIA.

30

Chickens used in the reversion to virulence study were CIAV-negative, SPF leghorn-type purchased from SPAFAS, Storrs CT. Three-week-old chickens were

5 delivered banded for identification and at that time all were bled for CIAV serology to determine the CIAV serological status (ELISA; IDEXX CAV Kit) of the birds. At four weeks of age, eight to thirteen (backpassages 2-4) or twenty-four to twenty-eight (backpassages 1 and 5) chickens per virus backpassage were vaccinated with a 10 µl dose ($10^{5.8}$ TCID₅₀, 1st backpassage; a 20% suspension of a pooled tissue
10 homogenate from the preceding backpassage given at a rate of 10 µl / bird, 2nd through 5th backpassage) via the wing web route. This series of five backpassages occurred over an eight-week period.

Liver, spleen and thymus were removed from eight euthanized chickens per backpassage at seven days post vaccination (DPV) to prepare a 20% suspension of a
15 pooled tissue homogenate (Waring Blender) in RPMI 1640 medium containing antibiotics, but no serum and used as working stock in the inoculation of chickens for backpassage and virus isolation in MSB-1 cells according to the procedure of Yuasa et al. [Nat'l. Inst. Anim. Health Q (Tokyo) 23:75-77,1983].

All of the chickens of each backpassage were observed daily for clinical
20 signs for seven (backpassages 2-4) or twenty-one DPV and the findings recorded. Blood was collected from all remaining chickens in backpassage one and five at fourteen and twenty-one DPV for hematocrit value determination. Chickens euthanized at seven and twenty-one DPV were examined for gross lesions characteristic of CIA.

25 An analysis of phenotypic stability was conducted on the virus recovered from the fifth backpassage in chickens as compared by standard indirect fluorescent antibody assay (IFA).

RESULTS

30

The results obtained reveal that the CIAV-DR did not induce morbidity and mortality, anemia and gross lesions characteristic of CIA when subjected to five

5 serial backpassages in chickens. Additionally, it was demonstrated that the CIAV remained phenotypically stable in the process.

Results of pre-trial blood samples for CIAV serological status, virus recovery from tissue homogenate extracts and post-mortem and hematocrit value findings at seven, fourteen and twenty-one DPV for the five backpassages are given in tables 1-

10 5. A summary of the virus recovery, hematocrit value and post-mortem examination results are given in table 6.

SUMMARY

15 This reversion to virulence study conducted with a live CIAV-DR, administered by wing web to four week old chickens, demonstrated that the virus did not revert to virulence when subjected to five serial backpassages, based on clinical observations and postmortem examinations.

20

5 **Table 1. ELISA, Virus Recovery, Hematocrit and Post-mortem Results for the First Serial Backpassage.**

<u>Bird No.</u>	<u>Band No.</u>	<u>ELISA S/N</u>	<u>Hematocrit</u> <u>14d/21d</u>	<u>CLAV SGL***</u>
1	1	1.09*	35 / 30**	None
2	2	1.15	29 / 31	None
3	3	1.13	30 / 30	None
4	4	1.16	30 / 33	None
5	5	1.25	NA / NA	None
6	6	1.24	35 / 36	None
7	7	1.31	NA / NA	None
8	8	0.91	NA / NA	None
9	9	0.77	34 / 29	None
10	10	1.06	30 / 31	None
11	11	1.14	34 / 32	None
12	12	1.25	30 / 31	None
13	14	1.32	NA / NA	None
14	15	1.13	34 / 37	None
15	16	0.95	31 / 27	None
16	17	1.08	NA / NA	None
17	18	1.14	32 / 30	None
18	19	1.2	32 / 34	None
19	20	1.3	34 / 31	None
20	21	1.35	NA / NA	None
21	22	1.41	NA / NA	None
22	23	0.96	NA / NA	None
23	25	1.1	30 / 28	None
24	26	1.18	34 / 32	None
25	27	1.29	32 / 32	None
26	29	1.39	29 / 30	None
27	30	1.38	35 / 34	None
28	31	1.04	32 / 33	None

10 **Virus Recovery from a Pooled Tissue Homogenate = Positive**

* S/N Ratios > 0.6 = Negative (IDEXX Kit Interpretation)

** Hematocrit Value > 25 = Negative

*** Specific Gross Lesions

15

5 **Table 2. ELISA, Virus Recovery and Post-mortem Results for the Second Serial Backpassage.**

<u>Bird No.</u>	<u>Band No.</u>	<u>ELISA S/N</u>	<u>CIAV SGL**</u>
1	32	1.06*	None
2	33	1.1	None
3	34	1.02	None
4	35	0.93	None
5	36	1.01	None
6	37	0.98	None
7	38	1.03	None
8	39	1	None
9	40	0.97	None
10	41	0.99	None
11	42	1	None
12	43	0.96	None
13	44	0.93	None

Virus Recovery from a Pooled Tissue Homogenate = Positive

10

* S/N Ratios > 0.6 = Negative (IDEXX Kit Interpretation)

** Specific Gross Lesions

15

5

Table 3. ELISA, Virus Recovery and Post-mortem Results for the Third Serial Backpassage.

<u>Bird No.</u>	<u>Band No.</u>	<u>ELISA S/N</u>	<u>CIAV SGL**</u>
1	45	0.9*	None
2	46	0.94	None
3	47	0.61	None
4	48	0.78	None
5	49	0.7	None
6	50	0.84	None
7	51	0.83	None
8	52	0.97	None
9	53	0.88	None
10	54	0.81	None
11	55	0.78	None
12	56	0.83	None
13	57	0.85	None

10 Virus Recovery from a Pooled Tissue Homogenate = Positive

* S/N Ratio > 0.6 = Negative (IDEXX Kit Interpretation)

** Specific Gross Lesions

15

5 **Table 4. ELISA, Virus Recovery and Post-mortem Results the Fourth Serial Backpassage.**

<u>Bird No.</u>	<u>Band No.</u>	<u>ELISA S/N</u>	<u>CIAV SGL**</u>
1	59	0.93*	None
2	60	0.9	None
3	61	0.86	None
4	62	0.9	None
5	63	0.88	None
6	64	0.87	None
7	67	0.83	None
8	70	0.95	None

Virus Recovery from a Pooled Tissue Homogenate = Positive

10

* S/N Ratio > 0.6 = Negative (IDEXX Kit Interpretation)

** Specific Gross Lesions

15

5

Table 6. Summary of Hematocrit, Virus Recovery and Post-mortem Results of Chickens.

<u>Back</u>		<u>Virus</u>	
<u>Passage</u>	<u>Hematocrit</u>	<u>Recovery</u>	<u>Post-Mortem</u>
1	0/20*	1/1**	0/28
2	-	1/1	0/13
3	-	1/1	0/13
4	-	1/1	0/8
5	0/16	1/1	0/24

10

* Number Positive/Number in Group

**Virus Recovery for a Pooled Tissue Homogenate

15

5 **Table 5. ELISA, Virus Recovery, Hematocrit and Post-mortem Results for the Fifth Serial Backpassage.**

<u>Bird No.</u>	<u>Band No.</u>	<u>ELISA S/N</u>	<u>Hematocrit 14d/21d</u>	<u>CIAV SGL***</u>
1	2	0.81*	NA / NA	None
2	3	0.61	32 / 34**	None
3	4	0.72	36 / 31	None
4	5	0.79	33 / 32	None
5	6	0.87	32 / 35	None
6	7	1.09	NA / NA	None
7	9	0.7	34 / 35	None
8	10	0.79	NA / NA	None
9	11	0.9	NA / NA	None
10	13	0.93	31 / 33	None
11	14	1.03	NA / NA	None
12	15	0.97	32 / 35	None
13	18	0.8	26 / 30	None
14	19	0.84	35 / 33	None
15	20	0.92	33 / 33	None
16	21	0.91	26 / 32	None
17	23	1.05	29 / 35	None
18	24	0.61	NA / NA	None
19	25	0.89	28 / 35	None
20	26	0.92	30 / 30	None
21	28	0.97	NA / NA	None
22	29	0.96	33 / 35	None
23	30	0.99	32 / 35	None
24	31	0.95	NA / NA	None

Virus Recovery from a Pooled Tissue Homogenate = Positive

* S/N Ratio > 0.6 = Negative (IDEXX Kit Interpretation)

** Hematocrit Value > 25 = Negative

*** Specific Gross Lesions

5

EXAMPLE 5**RESULTS OF A SHED/SPREAD AND VERTICAL TRANSMISSION STUDY****10 CONDUCTED IN SPF CHICKENS FOLLOWING WING WEB****ADMINISTRATION OF A LIVE CHICKEN ANEMIA VIRUS VACCINE****INTRODUCTION**

15

A host animal shed/spread and vertical transmission study was conducted in chicken infectious anemia virus (CIAV)-negative, SPF chickens on a chicken infectious anemia virus, Del-Ros strain, (CIAV-DR) administered by the wing web route. To assess shed and spread of CIAV live vaccine to contact controls, cloacal swabs were collected from vaccinated and contact control chickens for a 4 week post vaccination (p.v.) period and assayed for virus isolation in MSB-1 cells. To evaluate vertical transmission (i.e., p.v.) of CIAV live vaccine, pools of livers of 19-day-old embryos derived from eggs laid by vaccinated hens were assayed for virus by isolation in MSB-1 cells and by PCR detection.

25

PROCEDURE

The methods used to determine the shed/spread and vertical transmission of a new CIA master seed virus were conducted in CIAV-negative, SPF chickens vaccinated at 12 weeks of age. The possible shed and spread of wing web administered CIAV vaccine (live virus) was evaluated by collecting cloacal swabs from vaccinated and contact control chickens for a 4 week p.v. period followed by

30

5 virus isolation attempts in MSB-1 cells. The possibility of vertical transmission of live CIAV vaccine was examined by assaying pools of livers of 19-day-old embryos derived from all of the fertile eggs laid by all of the vaccinated hens for virus by isolation in MSB-1 cells and by PCR detection. Livers of embryos from 3 settings of eggs from negative control hens were evaluated in the same manner.

10 Chickens used in the shed/spread and vertical transmission study were CIAV-negative, SPF leghorn-type (SPF flock L103) purchased from SPAFAS. Birds were banded for identification. Ten randomly selected chickens at 12 weeks of age were bled for CIAV serology to confirm the negative status (ELISA; IDEXX CAV Kit) of the birds. On the same day, thirty-seven chickens (30 females and 7 males)
15 were vaccinated with a 10 µl dose ($10^{4.3}$ TCID₅₀) of the live CIAV vaccine by the wing-web route. Fifteen females (same source and hatch) were intermixed with the vaccinates as contact controls. Negative control chickens from the same source and hatch were maintained. Chickens of both groups were observed daily for morbidity and mortality and findings recorded for the duration of the study period.

20 Cloacal swab collections from fifteen randomly selected vaccinated chickens and the fifteen contact controls were made at 3-7 day intervals for a 4 week p.v. period. Cloacal swabs were pooled for virus reisolation by combining 3 groups of 5 swabs per treatment per sampling time. Virus recovery attempts were made in MSB-1 cells according to the procedure of Yuasa et al. [Natl. Inst. Anim. Health Q
25 (Tokyo) 23:75-77, 1983].

Livers were aseptically collected from live and dead embryos (derived from fertile eggs laid by vaccinated and negative control hens for a 3 week p.v. period) at 19 days of incubation and packaged/ stored (-20° C) in pools of 3-6 livers for future processing. Twenty percent (w/v) liver (pools) suspensions were prepared in RPMI
30 1640 medium plus 5% FBS for virus reisolation in MSB-1 cells according to the procedure of Yuasa et al. [Natl. Inst. Anim. Health Q (Tokyo) 23:75-77, 1983].

Prior to initiating a CIAV isolation procedure on test hens, an assessment of the

5 sensitivity of the CIAV isolation method outlined in the "shed/spread and vertical transmission protocol" was conducted. Briefly, this procedure entailed harvesting
livers from CIAV-antibody free SPF embryos at 19 days of incubation and preparing
four pools of five livers each. One liver pool was maintained as a negative control;
second, third and fourth pools were inoculated with 10, 100 and 1000 TCID₅₀ of
10 CIAV per gram of tissue, respectively.

In addition to virus reisolation assays conducted, attempts to detect CIAV by
PCR according to the procedure of Taylor and Ryncarz (Center for Veterinary
Biologics Laboratory, NVSL, VS, APHIS, USDA, Ames, IA) were undertaken.

15

RESULTS

The results revealed that 10^{4.3} TCID₅₀ of the CIAV-DR administered to
breeders at 12 weeks of age via the wing web is shed for as much as 21 days and that
it will spread to contact controls. However, the virus was not vertically transmitted
20 by breeders to their progeny as demonstrated by virus reisolation and PCR assays.
The breeders did not exhibit any adverse clinical effects from the vaccine
administration.

Results of ELISA on pre-trial blood samples confirmed that the chickens
used in this study were CIAV-antibody negative (table 1).

25

Results of virus reisolation attempts on cloacal swab pools of vaccinates and
contact controls are recorded in table 2. These data show that CIAV was being shed
by vaccinates as soon as 3 days p.v. and this shed continued through 21 days p.v.,
but not 28 days p.v. Additionally, the data show that the shed CIAV readily spread to
the contact controls who also shed the virus for similar period of time.

30

A summary of the virus reisolation and PCR detection attempts on embryo
liver suspensions derived from the fertile eggs of vaccinates and negative controls
are given in table 3. These data reveal that CIAV could not be isolated from embryo

- 5 liver suspensions of negative control and vaccinates by passage in MSB-1 cells or be
detected by PCR. The results of a CIAV isolation sensitivity assessment in MSB-1
cells demonstrated that varying levels of CIAV (i.e., 10-1000 TCID₅₀/gram of
tissue) was detected by this method following several cell culture passages (table 4).
There was complete correlation in the results obtained using these two methods on
10 test samples.

SUMMARY

- 15 This shed/spread and vertical transmission study was based on an effort to
isolate and/or detect live CIAV in cloacal swabs and fertile eggs (i.e., embryo liver
suspensions) collected from wing web vaccinated ($10^{4.3}$ TCID₅₀/dose) and negative
control hens. The results demonstrated that the virus was shed and spread for a
limited period of time (21 dpv) but that this virus was not transmitted vertically
when administered at 12 weeks of age.

20

Table 1. Pre-Trial Blood Sample ELISA Results.

<u>Bird No.</u>	<u>Band No.</u>	<u>S/N Ratio</u>	<u>CIAV Serol. Status</u>
1	554	0.91	Neg ^a
2	557	0.93	Neg.
3	565	0.92	Neg.
4	566	0.96	Neg.
5	574	0.96	Neg.
6	579	1	Neg.
7	584	1	Neg.
8	585	1	Neg.
9	731	0.99	Neg.
10	740	0.99	Neg.

- 25 ^a Negative = S/N Ratio > 0.6 (IDEXX Kit Interpretation)

5

Table 2. Shed/Spread: Summary of Virus Reisolation from Cloacal Swab Pools of Vaccinated and Contact Control Chickens.

Cloacal Swab (dpv) ^a	Vaccinate Cloacal Swab Pools			Contact Control Cloacal Swab Pools		
	<u>1</u>	<u>2</u>	<u>3</u>	<u>1</u>	<u>2</u>	<u>3</u>
3	N ^b	P ^c	N	N	N	P
7	P	P	P	P	P	P
12	N	P	N	N	P	N
16	P	P	N	N	N	P
21	P	P	P	P	N	N
28	N	N	N	N	N	N

10

^a Cloacal Swab Collection (Days Post Vaccination).^b Negative^c Positive = Characteristic CIAV CPE Observed

5 **Table 3. Vertical Transmission: Summary of Virus Reisolation and PCR Detection Assays on Embryo Liver Suspensions Derived from the Fertile Eggs of Vaccinates and Negative Controls.**

<u>Treatment</u>	<u>Virus Reisolation</u>	<u>PCR Detection</u>
1 ^a	0/12 ^b	0/12
2a ^c	0/17	0/17
2b	0/15	0/15
2c	0/19	0/19
2d	0/18	0/18
Pos. Con. ^d	6/6	5/6
Neg. Con. ^e	0/6	0/6

^a SPAFAS Negative Controls

^b Number Positive / Total Tested

^c Vaccinates - four groups (2a-2d)

^d Positive Controls (MSB-1 Propagated Del-Ros and Texas Strains of CIAV)

^e Negative Controls (MSB-1 cells and/or Reagent Mix)

15 **Table 4. Results of a CIAV Isolation Sensitivity Assessment.**

<u>Treatment</u>	<u>MSB-1 Passages</u>					
	<u>1</u>	<u>2</u>	<u>3</u>	<u>4</u>	<u>5</u>	<u>6</u>
<u>10 TCID₅₀</u> ^a	0/5 ^b	0/5	0/5	0/5	0/5	5/5
<u>100 TCID₅₀</u>	0/5	0/5	0/5	0/5	0/5	5/5
<u>1000 TCID₅₀</u>	0/5	0/5	0/5	0/5	3/5	5/5
<u>Uninf. Cont.</u> ^c	0/5	0/5	0/5	0/5	0/5	0/5

^a TCID₅₀ / Gram of Tissue

^b Number Positive (Characteristic CIAV CPE Observed) / Total

^c Uninfected Controls

5 EXAMPLE 6**EFFICACY STUDY CONDUCTED IN PROGENY OF SPF CHICKENS
34 AND 49 WEEKS FOLLOWING WING WEB ADMINISTRATION
OF A LIVE CHICKEN ANEMIA VIRUS VACCINE**

10

INTRODUCTION

A study to evaluate vaccine efficacy and duration of immunity (DOI) at 34 and 49 weeks post wing web vaccination was conducted by challenging day-old progeny of hens vaccinated with a chicken infectious anemia virus, Del Ros strain, (CIAV-DR). The study assessed CIAV maternal antibody protection (passive immunity) provided to chicks against a challenge with virulent CIAV.

PROCEDURE

20

Efficacy and duration of immunity of the were conducted in the progeny of CIAV-negative, SPF chickens vaccinated at 9 weeks of age with CIAV vaccine administered via the wing web route. Duration of immunity was evaluated by challenging progeny, hatched from fertile eggs laid by hens at 34 and 49 weeks post vaccination, followed by observations for clinical signs, hematocrit value determinations and post-mortem examinations for gross lesions characteristic of CIA.

Chickens used in this study were CIAV-negative, SPF leghorn-type purchased from SPAFAS. Birds were wing-banded for identification. Ten randomly selected chickens at 9-weeks-of-age were bled for CIAV serology to confirm the negative serological status (ELISA, IDEXX CAV Kit) of the birds. On the same day, 70 chickens (60 females and 10 males) were vaccinated with a 10 µl dose ($10^{4.2}$

5 TCID₅₀) of the live CIAV vaccine by the wing web route. Negative control chickens from the same source and hatch were maintained.. The dose was determined as the average of 5 replicate titers conducted immediately after vaccination. Chickens of both groups were observed daily for morbidity and mortality and the findings recorded for the duration of the study period.

10 A one-week collection of eggs from 52 vaccinated hens (43-weeks-of-age) were used to evaluate progeny of breeders at 34 weeks post CIAV vaccination (DOI Test 2). A second one-week collection of eggs from 48 vaccinated hens (58 weeks of age to assess progeny of breeders at 49 weeks post CIAV vaccination (DOI Test 3).

Forty-day-old chicks, each from CIAV vaccinated and non-vaccinated
15 breeders, were challenged with liver homogenate extract derived from chicks inoculated with a Texas field isolate of CIAV. Each chick was inoculated intra-abdominally with approximately 10^{2.6} CID₅₀ per 0.2 ml. Negative control groups consisted of 25 chicks.

Chicks of all treatment groups were maintained in separate filtered-air,
20 negative-pressure isolators and observed daily for depression, ruffled feathers and mortality. Blood samples were collected from all of the chicks at 14 and 21-22 days post challenge for hematocrit value determinations as a measure of anemia. The procedure used for determining hematocrit values was that of Rosenberger and Cloud (Avian Dis. 33:753-759, 1989). Additionally, chicks of all treatment groups
25 were examined for gross lesions characteristic of CIA (i.e., pale bone marrow, swelling and discoloration of the liver and spleen and hemorrhagic lesions in the skin and muscles) at 21-22 days post challenge. Treatment comparisons were based on the number of individuals within a treatment (per total examined) exhibiting specific gross lesions of CIA.

30

5

RESULTS

The results of the two DOI challenge tests, reported herein, demonstrated that $10^{4.2}$ TCID₅₀ of virus administered to breeders at 9 weeks of age via the wing web protected progeny against morbidity and mortality, anemia and gross lesions characteristic of CIA through 49 weeks post vaccination as determined by statistical evaluation.

Pre-study blood sample ELISA results were found to confirm the CIAV-negative status of the semi-mature chickens acquired from SPAFAS for use in this study and are presented in table 1.

Results of hematocrit value determinations, clinical-sign findings and post-mortem examinations of CIAV challenged and non-challenged day-old chicks are recorded in tables 2, 3 and 4 (DOI Test 2) and 8, 9 and 10 (DOI Test 3); tables 5 and 11, respectively, summarize this information. Chicks with gross lesion scores ≥ 1 , for any one of the tissues examined (i.e., liver, muscle, bone marrow and thymus), were recorded as CIA positive (tables 5 and 11). The death of chicks (table 2; derived from CIAV vaccinated breeders) numbered 3, 8, 22, 26, 27 and 40 in DOI test 2 resulted from suffocation in an isolator glove. Statistical evaluations (Fisher's Exact Probability Test; tables 6 and 12) of hematocrit values and clinical signs of Test 2 and 3 chicks revealed that progeny of CIAV vaccinated versus non vaccinated breeders were protected against anemia and mortality at a statistically significant level ($p < 0.001$) when challenged with a virulent field isolate of CIAV. A statistically significant difference ($p = 0.027$) in morbidity was demonstrated among challenged progeny in DOI Test 3. Statistical assessment (Mann-Whitney Test; tables 7 and 13) of gross lesion scores revealed similar findings as those reported above; i.e., a statistically significant difference and in the bone marrow ($p < 0.001$ and $p = 0.021$, respectively) and thymus ($p < 0.001$) gross lesion scores of progeny

- 5 derived from vaccinated versus non-vaccinated breeders. No significant differences were demonstrated for liver and muscle lesions among challenged progeny.

SUMMARY

- 10 This assessment of vaccine efficacy and immunity duration was based on a day-old, intra abdominal challenge of progeny derived from breeders vaccinated at 9 weeks of age with live CIAV-DR vaccine administered by the wing web route. The results revealed that the CIAV vaccine induced maternal antibodies which protected chicks at a statistically significant difference of $p < 0.05$, against a virulent challenge
- 15 with a field strain of CIAV, based on evidence of anemia at 14 and 21 days post challenge, clinical signs and gross lesions of the bone marrow and thymus when compared to challenge control chicks.

20

5 **Table 1.** Pre-Trial Blood Sample ELISA Results of 9 Week Old Chickens Prior to Vaccination with Wing Web Administered CIAV to Confirm Negative Serological Status.

<u>Bird No.</u>	<u>Band No.</u>	<u>S/N Ratio</u>	<u>CIAV Serol. Status^a</u>
1	602	0.88	Neg ^b
2	608	0.84	Neg
3	616	0.9	Neg
4	620	0.81	Neg
5	621	0.78	Neg
6	627	0.85	Neg
7	631	0.87	Neg
8	634	0.82	Neg
9	644	0.85	Neg
10	661	0.7	Neg

^a CIAV Serological Status

^b Negative = S/N Ratio > 0.6 (IDEXX Kit Interpretation)

5 Table 2. Test 2 Hematocrit Values, Clinical Signs and CIA Gross Lesion Scores of Chicks Challenged at 34 Weeks Following Wing Web Administered CIA Vaccine.

Bird No.	Hematocrit Values		Clin. Signs ^a		Gross Lesion Scores		
	14 Day	21 Day	Mor./Mort. ^c	Liver	BM ^d	Thymus	Muscle
	pc ^b	pc					
1	28	35	N/N	O ^e	0	0	0
2	33	32	N/N	0	0	0	0
3	35	ND ^f	N/NCAM ^g	0	0	0	0
4	32	39	N/N	0	0	0	0
5	32	34	N/N	0	0	0	0
6	26	27	N/N	0	0	0	0
7	28	32	N/N	0	0	0	0
8	32	ND	N/NCAM	0	0	0	0
9	32	33	N/N	0	0	0	0
10	32	24 ^h	N/N	0	2	1	1
11	26	12	P/N ⁱ	0	2	2	0
12	33	26	N/N	0	2	2	0
13	27	31	N/N	0	0	0	0
14	32	35	N/N	0	0	0	0
15	33	32	N/N	0	0	0	0
16	60	39	N/N	0	0	0	0
17	58	37	N/N	0	0	0	0
18	30	24	N/N	0	1	2	0
19	33	34	N/N	0	0	0	0
20	21	17	N/N0	0	3	2	0
21	58	35	N/N	0	0	0	0
22	32	ND	N/NCAM	0	0	0	0
23	33	37	N/N	0	2	1	0
24	34	36	N/N	0	0	0	0
25	29	33	N/N	0	0	0	0

10 Continued on next page

5 **Table 2. (continued) Test 2 Hematocrit Values, Clinical Signs and CIA Gross Lesion Scores of Chicks Challenged at 34 Weeks Following Wing Web Administered CIA Vaccine.**

Bird No.	Hematocrit Values		Clin. Signs ^a		Gross Lesion Scores		
	14 Day	21 Day	Mor./Mort. ^c	Liver	BM ^d	Thymus	Muscle
	pc ^b	pc					
26	30	ND ^f	N/NCAM ^g	0 ^e	0	0	0
27	34	ND	N/NCAM	0	0	0	0
28	35	32	N/N	0	0	0	0
29	35	27	N/N	0	0	0	0
30	28	23 ^h	N/N	0	1	2	0
31	30	31	N/N	0	0	0	0
32	ND	ND	N/P ⁱ	0	0	0	0
33	33	35	N/N	0	0	0	0
34	34	41	N/N	0	0	0	0
35	27	36	N/N	0	0	0	0
36	32	34	N/N	0	0	0	0
37	30	21	N/N	0	0	0	0
38	33	36	N/N	0	0	0	0
39	31	34	N/N	0	0	0	0
40	30	ND	N/NCAM	0	0	0	0

10

Pos./Tot. ^j	1/39	6/33	1/40 / 1/34	0/40	7/40	7/40	1/40
------------------------	------	------	-------------	------	------	------	------

^a Clinical Signs^b Post Challenge^c Morbidity (Depression and/or Ruffled Feathers) / Mortality^d Bone Marrow15 ^e 0 = Normal; 1 = Slight; 2 = Moderate; 3 = Severe Not Done^f Not None^g Negative / Non-CIAV Associated Mortality^h Hematocrit Values of ≤ 25 = Anemiaⁱ Negative / Positive (CIAV Associated Mortality)20 ^j Number Positive / Total

5 ... **Table 3. Test 2 Hematocrit Values, Clinical Signs and CIA Gross Lesion Scores of Challenged Chicks from Non-Vaccinated Breeders.**

<u>Bird No.</u>	<u>Hematocrit Values</u>		<u>Clin. Signs^a</u>		<u>Gross Lesion Scores</u>		
	<u>14 Day</u> <u>pc^b</u>	<u>21</u> <u>Day</u> <u>pc</u>	<u>Mor./Mort.^c</u>	<u>Liver</u>	<u>BM^d</u>	<u>Thymus</u>	<u>Muscle</u>
1	23 ^e	ND ^f	N/P ^g	0 ^h	2	3	1
2	18	ND	N/P	0	2	2	0
3	29	22	N/N	0	0	0	0
4	26	20	P/N	0	0	3	0
5	20	ND	N/P	0	3	2	1
6	28	26	N/N	0	0-	0	0
7	21	57	N/N	0	0	3	0
8	20	ND	N/P	0	3	3	0
9	21	21	N/N	0	2	2	0
10	18	ND	N/P	0	3	3	2
11	32	24	N/N	0	2	1	0
12	21	ND	N/P	0	3	3	1
13	26	24	N/N	0	0	0	0
14	25	19	N/N	0	0	1	0
15	25	45	N/N	0	2	1	0
16	28	30	N/N	0	2	3	0
17	27	10	P/N	0	3	3	0
18	16	ND	P/P	0	2	2	0
19	22	25	N/N	0	0	0	0
20	18	24	N/N	0	0	2	2
21	20	ND	N/P	0	3	2	1
22	28	20	N/N	0	1	3	0
23	26	15	P/N	0	2	1	0
24	22	28	N/N	0	0	0	0
25	17	ND	P/P	2	3	3	2

10 Continued on next page

5 **Table 3. (continued) Test 2 Hematocrit Values, Clinical Signs and CIA Gross Lesion Scores of Challenged Chicks from Non-Vaccinated Breeders.**

Bird No.	Hematocrit Values		Clin. Signs ^a		Gross Lesion Scores		
	14 Day pc ^b	21 Day pc	Mor./Mort. ^c	Liver	BM ^d	Thymus	Muscle
26	24 ^e	30	N/N	0 ^h	0	2	0
27	40	56	N/N	0	2	2	0
28	30	15	N/N	0	2	2	0
29	29	29	N/N	0	0	0	0
30	31	27	N/N	0	1	2	0
31	25	32	N/N	0	1	2	0
32	25	13	P/N	0	3	3	0
33	21	27	N/N	0	0	0	0
34	28	21	N/N	0	2	2	0
35	30	28	N/N	0	0	0	0
36	30	ND ^f	N/P ^g	0	3	3	1
37	28	23	N/N	0	0	0	0
38	70	13	N/N	0	2	1	0
39	23	25	N/N	0	0	1	0
40	25	27	N/N	0	0	0	0
Pos./Tot. ⁱ	22/40	17/30	6/40 / 10/40	1/40	24/40	30/40	8/40

10

^a Clinical Signs^b Post Challenge^c Morbidity (Depression and/or Ruffled Feathers) / Mortality^d Bone Marrow15 ^e Hematocrit Values ≤ 25 = Anemia^f Not None^g Negative / Positive (CIAV Associated Mortality)^h 0 = Normal; 1 = Slight; 2 = Moderate; 3 = Severeⁱ Number Positive / Total

20

5 **Table 4. Test 2 Hematocrit Values, Clinical Signs and CIA Gross Lesion Scores of Chicks from Non-Vaccinated Breeders; Not Challenged.**

Hematocrit Values			Clin. Signs^a	Gross Lesion Scores			
Bird No.	14 Day	21 Day	Mor./Mort.^c	Liver	BM^d	Thymus	Muscle
	pc^b	pc					
1	37	38	N/N ^e	0 ^f	0	0	0
2	38	35	N/N	0	0	0	0
3	35	30	N/N	0	0	0	0
4	40	35	N/N	0	0	0	0
5	36	37	N/N	0	0	0	0
6	38	36	N/N	0	0	0	0
7	35	36	N/N	0	0	0	0
8	28	38	N/N	0	0	0	0
9	NS ^g	35	N/N	0	0	0	0
10	31	NS	N/N	0	0	0	0
11	36	36	N/N	0	0	0	0
12	37	35	N/N	0	0	0	0
13	36	33	N/N	0	0	0	0
14	31	42	N/N	0	0	0	0
15	39	40	N/N	0	0	0	0
16	35	37	N/N	0	0	0	0
17	40	36	N/N	0	0	0	0
18	35	33	N/N	0	0	0	0
19	32	35	N/N	0	0	0	0
20	33	35	N/N	0	0	0	0
21	30	45	N/N	0	0	0	0
22	39	39	N/N	0	0	0	0

Table 4 continued on next page

10

5

Hematocrit Values			Clin. Signs ^a	Gross Lesion Scores			
Bird No.	14 Day	21 Day	Mor./Mort. ^c	Liver	BM ^d	Thymus	Muscle
	pc ^b	pc					
23	34	40	N/N	0	0	0	0
24	33	38	N/N	0	0	0	0
25	35	27	N/N	0	0	0	0
Pos./Tot. ^h	0/24	0/24	0/25 / 0/25	0/25	0/25	0/25	0/25

^a Clinical Signs^b Post Challenge10 ^c Morbidity (Depression and/or Ruffled Feathers) / Mortality^d Bone Marrow^e Negative / Negative^f 0 = Normal; 1 = Slight; 2 = Moderate; 3 = Severe^g No Sample15 ^h Number Positive / Total

Table 5. Summary of Test 2 Hematocrit, Morbidity, Mortality and CIA Gross Lesion Scores of Challenged and Non-Challenged Chicks.

20

Test Group	Hematocrit	Morbidity	Mortality	PM ^a
CIAV Vaccinated ^b	6/39 (15%) ^c	1/40 (3%)	1/34 (3%)	7/40 (18%) ^d
Non-Vaccinated ^b	33/40 (83%)	6/40 (15%)	10/40 (25%)	30/40 (75%)
Negative Control	0/25	0/25	0/25	0/25

^a Post-Mortem CIA Gross Lesion Scores^c Number Chicks Positive / Total^b Challenge Group^d Positive Chicks = Gross Lesion Scores ≥ 1

25

Table 6. Statistical Evaluation of Test 2 Hematocrit Values and CIA Clinical Signs of Challenged Chicks using Fisher's Exact Probability Test.

<u>Test Group</u>	<u>Hematocrit Values</u>		<u>Clinical Signs</u>		
	<u>14 Day pc^a</u>	<u>21 Day pc</u>	<u>Morbidity</u>	<u>Mortality</u>	<u>Combined</u>
CIAY Vaccinated	1/39	6/33	1/40	1/34	6/40 ^b
Non-Vaccinated	22/40	17/30	6/40	10/40	34/40
p value	<0.001	0.002	0.054	0.007	<0.001

^a Post Challenge

^b Combined Hematocrit Values and Clinical Signs

5

Table 7. Statistical Evaluation of Test 2 CIA Gross Lesion Scores of Challenged Chicks from Vaccinated and Non-Vaccinated Breeders using the Mann-Whitney Test

p value	Gross Lesion Scores ^a				
	Liver	<u>BM^b</u>	Thymus	<u>Muscle</u>	<u>Combined^c</u>
	0.847	<0.001	<0.001	0.173	<0.001

^a Raw Data Found in Tables 2 and 3

^b Bone Marrow

^c Combined Gross Lesion Scores

15

5 **Table 8. Test 3 Hematocrit Values, Clinical Signs and CIA Gross Lesion Scores of Chicks Challenged at 49 Weeks Following Wing Web Administered CIA Vaccine.**

<u>Bird No.</u>	<u>Hematocrit Values</u> <u>Scores</u>		<u>Clin. Signs^a</u>		<u>Gross Lesion</u>		
	<u>14 Day pc^b</u>	<u>21 Day pc</u>	<u>Mor./Mort.^c</u>	<u>Liver</u>	<u>BM^d</u>	<u>Thymus</u>	<u>Muscle</u>
1	31	45	N/N ^e	0 ^f	0	0	0
2	30	32	N/N	0	0	0	0
3	34	34	N/N	0	0	0	0
4	28	28	N/N	0	0	0	0
5	33	23g	N/N	0	0	0	0
6	32	30	N/N	0	0	0	0
7	24	36	N/N	0	0	0	0
8	49	32	N/N	0	0	0	0
9	35	30	N/N	0	0	0	0
10	31	31	N/N	0	0	0	0
11	34	27	N/N	0	0	0	0
12	33	35	N/N	0	0	0	0
13	43	27	N/N	0	0	0	0
14	41	33	N/N	0	0	0	0
15	25	30	N/N	0	0	0	0
16	35	31	N/N	0	0	0	0
17	30	32	N/N	0	0	0	0
18	32	35	N/N	0	0	0	0
19	30	33	N/N	0	0	0	0
20	32	28	N/N	0	0	0	0
21	33	32	N/N	0	0	0	0
22	34	33	N/N	0	0	0	0
23	29	30	N/N	0	0	0	0
24	30	27	N/N	0	0	2	0
25	29	30	N/N	0	0	0	0

10

Continued on next page

5 **Table 8. (continued) Test 3 Hematocrit Values, Clinical Signs and CIA Gross Lesion Scores of Chicks Challenged at 49 Weeks Following Wing Web Administered CIA Vaccine.**

Bird No.	Hematocrit Values		Clin. Signs ^a Mor./Mort. ^c	Liver	Gross Lesion Scores		
	14 Day pc ^b	21 Day pc			BM ^d	Thymus	Muscle
26	30	28	N / N ^e	0 ^f	0	0	0
27	52	30	N / N	0	0	0	0
28	35	35	N / N	0	0	0	0
29	30	27	N / N	0	0	0	0
30	50	26	N / N	0	0	1	0
31	35	31	N / N	0	0	0	0
32	35	34	N / N	0	0	0	0
33	20 ^g	30	N / N	0	0	0	0
34	31	30	N / N	0	0	0	0
35	32	28	N / N	0	0	0	0
36	30	37	N / N	0	0	0	0
37	35	38	N / N	0	0	0	0
38	34	32	N / N	0	0	0	0
39	35	30	N / N	0	0	0	0
40	31	32	N / N	0	0	0	0
Pos./Tot. ^h	3/40	1/40	0/40 / 0/40	0/40	0/40	2/40	0/40

10

^a Clinical Signs^b Post Challenge^c Morbidity (Depression and/or Ruffled Feathers) / Mortality^d Bone Marrow

15

^e Negative / Negative^f 0 = Normal; 1 = Slight; 2 = Moderate; 3 = Severe^g Hematocrit Values of ≤ 25 = Anemia^h Number Positive / Total

5 **Table 9. Test 3 Hematocrit Values, Clinical Signs and CIA Gross Lesion Scores of Challenged Chicks from Non-Vaccinated Breeders.**

<u>Bird No.</u>	<u>Hematocrit Values</u>		<u>Clin. Signs^a</u>	<u>Liver</u>	<u>Gross Lesion Scores</u>		
	<u>14 Day pc^b</u>	<u>21 Day pc</u>	<u>Mor./Mort.^c</u>		<u>BM^d</u>	<u>Thymus</u>	<u>Muscle</u>
1	19 ^e	ND ^f	N/P ^g	2 ^h	2	3	2
2	22	32	N/N	0	0	0	0
3	50	ND	P/P	0	0	3	0
4	32	28	N/N	0	0	2	0
5	31	27	N/N	0	2	0	0
6	32	29	N/N	0	0	0	0
7	26	19	N/N	0	0	2	0
8	30	27	N/N	0	0	0	0
9	23	ND	P/P	0	2	2	0
10	17	29	N/N	0	0	0	0
11	23	35	N/N	0	0	0	0
12	20	ND	N/P	0	3	3	0
13	18	ND	P/P	0	0	2	0
14	22	ND	N/P	0	2	3	1
15	44	13	N/N	0	2	2	0
16	30	32	N/N	0	0	1	0
17	14	ND	N/P	0	0	3	0
18	31	26	N/N	0	0	1	0
19	20	ND	N/P	0	2	3	0
20	23	10	N/N	0	2	2	0
21	33	20	N/N	0	0	2	0
22	23	ND	P/P	0	0	3	0
23	22	ND	N/P	0	0	3	0
24	29	27	N/N	0	2	2	0
25	30	15	N/N	0	0	1	0

10 Continued on next page

5 **Table 9. (continued) Test 3 Hematocrit Values, Clinical Signs and CIA Gross Lesion Scores of Challenged Chicks from Non-Vaccinated Breeders.**

Bird No.	Hematocrit Values		Clin. Signs ^a Mor./Mort. ^c	Liver	Gross Lesion Scores		
	14 Day pc ^b	21 Day pc			BM ^d	Thymus	Muscle
26	29	35	N/I N	0 ^h	0	0	0
27	24 ^e	33	N/N	0	0	0	0
28	27	20	N/N	0	0	0	0
29	32	19	N/N	0	2	1	0
30	25	ND ^f	P/P	2	0	3	1
31	22	18	N/N	0	1	2	0
32	33	34	N/N	0	0	0	0
33	23	ND	N/P ^g	0	2	3	0
34	25	35	N/N	0	0	0	0
35	16	ND	N/P	0	0	3	0
36	28	15	N/N	0	0	0	0
37	29	25	N/N	0	0	0	0
38	30	32	N/N	0	0	0	0
39	29	25	N/N	0	0	2	0
40	31	23	N/N	0	0	0	0

Pos./Tot.ⁱ 19/40 12/27 5/40 13/40 2/40 12/40 25/40 3/40

10

^a Clinical Signs^b Post Challenge^c Morbidity (Depression and/or Ruffled Feathers) / Mortality^d Bone Marrow

15

^e Hematocrit Values ≤ 25 = Anemia^f Not Done^g Negative / Positive (CIAV Associated Mortality)^h 0 = Normal; 1 = Slight; 2 = Moderate; 3 = Severeⁱ Number Positive / Total

20

5 **Table 10.** Test 3 Hematocrit Values, Clinical Signs and CIA Gross Lesion Scores of Chicks from Non-Vaccinated Breeders; Not Challenged.

Bird No.	Hematocrit Values		Clin. Signs ^a	Gross Lesion Scores			
	14 Day pc ^b	21 Day pc	Mor./Mort. ^c	Liver	BM ^d	Thymus	Muscle
1	35	34	N / N ^e	0 ^f	0	0	0
2	39	35	N / N	0	0	0	0
3	33	34	N / N	0	0	0	0
4	37	35	N / N	0	0	0	0
5	38	33	N / N	0	0	0	0
6	32	35	N / N	0	0	0	0
7	35	37	N / N	0	0	0	0
8	29	39	N / N	0	0	0	0
9	35	36	N / N	0	0	0	0
10	32	37	N / N	0	0	0	0
11	33	38	N / N	0	0	0	0
12	33	34	N / N	0	0	0	0
13	31	35	N / N	0	0	0	0
14	30	35	N / N	0	0	0	0
15	36	40	N / N	0	0	0	0
16	30	39	N / N	0	0	0	0
17	30	38	N / N	0	0	0	0
18	30	36	N / N	0	0	0	0
19	40	35	N / N	0	0	0	0
20	35	35	N / N	0	0	0	0
21	35	35	N / N	0	0	0	0
22	35	33	N / N	0	0	0	0
23	34	41	N / N	0	0	0	0
24	28	41	N / N	0	0	0	0
25	32	38	N / N	0	0	0	0
Pos./Tot. ^g	0/25	0/25	0/25 / 0/25	0/25	0/25	0/25	0/25

5

- ^a Clinical Signs
- ^b Post Challenge
- ^c Morbidity (Depression and/or Ruffled Feathers) / Mortality
- ^d Bone Marow

10

- ^e Negative / Negative
- ^f 0 = Normal; 1 = Slight; 2 = Moderate; 3 = Severe
- ^g Number Positive / Total

5 **Table 11. Summary of Test 3 Hematocrit, Morbidity, Mortality and Gross Lesion of Challenged and Non-Challenged Chicks.**

Test Group	Hematocrit	Morbidity	Mortality	PM ^a
CIAV Vaccinated ^b	4/40 (10%) ^c	0/40	0/40	2/40 (5%) ^d
Non-Vaccinated ^b	29/40 (73%)	5/40 (13%)	13/40 (33%)	26/40 (65%)
Negative Control	0/25	0/25	0/25	0/25

10 ^a Post-Mortem CIA Gross Lesion Scores
^b Challenge Group

^c Number Positive / Total
^d Positive Chicks = Gross Lesion Scores ≥ 1

15 **Table 12. Statistical Evaluation of Test 3 Hematocrit Values and Clinical Signs of Challenged Chicks using Fisher's Exact Probability Test**

Test Group	Hematocrit Values		Clinical Signs		
	14 Day pc ^a	21 Day pc	Morbidity	Mortality	Combined
CIAV Vaccinated	3/40	1/40	0/40	0/40	4/40 ^b
Non-Vaccinated	19/40	12/27	5/40	13/40	30/40
p value	<0.001	<0.001	0.027	<0.001	<0.001

^a Post Challenge

^b Combined Hematocrit Values and Clinical Signs

20

5

Table 13. Statistical Evaluation of Test 3 CIA Gross lesion Scores of Challenged Chicks from Vaccinated and Non-Vaccinated Breeders using the Mann-Whitney Test

10

	<u>Gross Lesion Scores^a</u>				
	<u>Liver</u>	<u>BM^b</u>	<u>Thymus</u>	<u>Muscle</u>	<u>Combined^c</u>
p value	0.7	0.021	<0.001	0.5637	<0.001

^a Raw Data Found in Tables 8 and 9

^b Bone Marrow

15

^c Combined Gross Lesion Scores

5

EXAMPLE 7

**EFFICACY OF A CHICKEN ANEMIA VIRUS VACCINE EVALUATED
BY MATERNAL ANTIBODY PROTECTION OF PROGENY FROM
CHICKENS 27 AND 37 WEEKS FOLLOWING DRINKING WATER
ADMINISTRATION THE VACCINE**

10

INTRODUCTION

15

Host animal efficacy and duration of immunity studies were conducted in chickens by challenge of day-old progeny hatched from 27 and 37 week-old hens, which were previously vaccinated with chicken infectious anemia virus, Del Ros strain (CIAV-DR) vaccine at 9 weeks of age by drinking water. The challenge procedure of progeny and parameters of measurement of efficacy by maternal antibody protection (passive immunity) provided by hens vaccinated in the drinking water were the same as for chicken anemia virus vaccine administered by the wing web route (see Example 6).

20

PROCEDURE

25

Progeny were hatched from fertile eggs laid 18 and 28 weeks post vaccination when hens were 27 and 37 weeks of age, respectively. Intra-abdominal challenge of day-old progeny was used to evaluate maternal antibody protection provided by CIAV-DR following drinking water vaccination of CIAV-negative SPF chickens at 9 weeks of age. Post challenge observations of progeny through 21 days of age included clinical signs, hematocrit value determinations and post-mortem examinations for gross lesions characteristic of chicken infectious anemia (CIA).

30

5 Chickens used for vaccination in this study were CIAV negative, SPF leghorn-type purchased from SPAFAS, Inc. Birds were wing banded for identification upon arrival. Twenty randomly selected chickens at 9 weeks of age were bled for CIAV serology to confirm negative serological status using the
10 IDEXX ELISA CIAV kit. On the same day, 40 females and 5 males designated as vaccinates were water starved and then permitted to drink water containing CIAV-DR vaccine. The average of five replicate titers of the CIAV vaccine conducted after vaccination in MSB-1 cells determined a dose contained $10^{5.5}$ TCID₅₀.
15 Negative control breeder chickens from the same source and hatch date were maintained. Two efficacy/duration of immunity studies identified as Study 1 and Study 2 were conducted on progeny from 27 and 37 week-old hens, respectively. Chicks were challenged at one day of age with CIAV. The challenge virus was liver homogenate extract derived from chicks inoculated with a Texas field isolate of CIAV. Each chick was inoculated intra-abdominally with approximately
20 $10^{2.6}$ CID₅₀ per 0.2 ml. Each study consisted of a group of progeny from non-vaccinated hens maintained as non-challenged negative controls, a group of CIAV challenged progeny from non-vaccinated hens that served as positive controls, and a group of CIAV challenged progeny from vaccinated hens. Chicks of all treatment groups
25 were maintained in filtered air, negative pressure isolation units and observed through 21 days for depression, ruffled feathers and mortality. Blood samples were collected from all chicks at 14 and 21 days post challenge (dpc) for hematocrit value determinations as a measure of anemia. The procedure used for determining hematocrit values was that of Rosenberger and Cloud (Avian Dis. 33:753-759,
30 1989). A chick with a hematocrit value of ≤ 25 was considered to be anemic. Additionally, chicks of all treatments were examined at 21 dpc for gross lesions characteristic of CIA including pale bone marrow, swelling and discoloration of the

5 liver and spleen, and hemorrhage lesions in the skin and muscles. Treatment comparisons were based on the number of individuals within a treatment (per total examined) exhibiting specific gross lesions of CIA. Data were statistically analyzed using Fisher's Exact Probability Test and Mann-Whitney Test.

10 RESULTS

Serological pre-vaccination serum samples using the IDEXX ELISA kit confirmed the CIAV negative status of the 9-week-old chickens acquired from SPAFAS, Inc. that were used in this study. ELISA results are given in Table 1.

15 Results of the two studies reported herein demonstrated that $10^{5.5}$ TCID₅₀ of CIAV-DR vaccine administered by drinking water to 9-week-old pullets significantly protected progeny at $p < 0.05$ through 37 weeks of age (i.e. 28 weeks post vaccination) when compared to progeny from non-vaccinated hens. A gross lesion score ≥ 1 for any one of the tissues examined (i.e. liver, bone marrow, thymus
20 and muscle) was recorded as a CIA positive chick. There was a significant difference at $p < 0.05$ in progeny of vaccinated hens compared to non-vaccinated hens in Study 1 and Study 2 against morbidity and mortality, anemia, and gross lesions characteristic of CIA.

25 Results of Study 1

Forty day-old chicks from non-vaccinated breeders challenged with CIAV were evaluated in this study as the positive control group. The death of one of 25 chicks from the non-challenged negative control group occurred early in the test
30 period and could not be attributed to any specific cause. Twenty-four negative controls remained for evaluation. A power outage in the isolator holding 40 challenged chicks from the CIAV vaccinated hens at 3 dpc and resulted in the death

5 of 15 of the 40 chicks leaving 25 chicks of this treatment group for evaluation in this study (See Table 4). One chick from the CIAV vaccinated group died at 5 dpc. The chick had no gross lesions or clinical signs of CIAV. Therefore, mortality was ruled due to non-CIAV related causes.

The 24 non-challenged negative control chicks did not exhibit morbidity, 10 mortality or gross lesions of CIA. One of 22 serum samples collected from chicks at 21 dpc had a hematocrit value of 23, but the chick had no other characteristic sign of CIA. Results are given in Table 2.

The challenge procedure induced CIA in progeny from non-vaccinated breeders. Hematocrit values ≤ 25 at either 14 or 21 dpc were demonstrated in 36 of 15- 40 (90%) positive control chicks. Morbidity was noted in 5 of 40 (12.5%) chicks, whereas, mortality was experienced in 10 of 40 (25%) chicks. Gross lesions were evident in 33 of 40 (82.5%) chicks. Results are given in Table 3.

Statistical evaluations by Fisher's Exact Probability Test of hematocrit values demonstrated that there was a significant difference at $p < 0.001$ against 20 anemia, a significant difference at $p = 0.012$ against combined morbidity and mortality, and a significant difference of $p < 0.001$ in the number of birds with CIA gross lesion scores in progeny from vaccinated breeders compared to progeny from non-vaccinated breeders. Statistical analysis of gross lesion scores by Mann-Whitney Test demonstrated a significant difference of $p < 0.001$ in the bone marrow 25 and the thymus. There was a significant difference at $p < 0.001$ by Fisher's Exact Test of the number of birds with gross lesions of progeny from vaccinated breeders compared to progeny from non-vaccinated breeders. Results and statistical evaluations given in Tables 4, 5, 6 and 7.

30 Results of Study 2

The groups of study 2 consisted of non-challenged negative controls from

5 non-vaccinated hens (n=25), CIAV challenged controls from non-vaccinated hens (n=40) and CIAV challenged progeny from 37-week-old CIAV vaccinated breeder hens (n=40). Throughout the 21-day test, negative control chickens remained free of anemia as determined by hematocrit values, morbidity, mortality and gross lesion scores associated with CIA. Results are given in Table 8.

10 The CIAV positive control chicks exhibited lowered hematocrit values, clinical signs and gross lesions typical of CIA. Hematocrit values ≤ 25 at either 14 or 21 dpc were demonstrated in 32 of 39 (82.1%) positive control chicks. Morbidity was noted in 6 of 40 (15.0%) chicks, and mortality was experienced in 12 of 40 (30.0%) chicks. Gross lesions were evident at post mortem in 24/40 (60.0%) of
15 chicks. Results are given in Table 9.

Following CIAV challenge a significant difference at $p < 0.05$ was demonstrated in progeny from CIAV vaccinated hens compared to progeny from non-vaccinated hens in hematocrit values at 14 and 21 dpc, in morbidity and mortality, and in gross lesions scores. Fisher's Exact Probability Test of hematocrit
20 values demonstrated a significant difference at $p < 0.001$ against anemia, a significant difference at $p < 0.001$ against morbidity and mortality, and a significant difference at $p < 0.001$ in the number of birds with CIA gross lesions scores. Results and statistical evaluations are given in Tables 10, 11, 12 and 13. Please note that one chick from
the CIAV vaccinated group died 3 dpc and another at 8 dpc. The chicks had no
25 gross lesions or clinical signs of CIAV. Therefore, mortality was ruled due to non-CIAV related causes.

SUMMARY

30 These studies demonstrated that CIAV maternal antibody provided significant protection against CIA at $p < 0.05$ to progeny of SPF white leghorn type chickens, which were previously vaccinated at 9 weeks of age with the live chicken

- 5 infectious anemia virus vaccine administered via the drinking water. The protection was assessed on the basis of clinical signs, morbidity/mortality, and CIAV specific lesions at necropsy. These studies demonstrated that maternal antibody protection was provided to chicks by hens through at least 37 weeks of age (28 weeks post vaccination).

10

Table 1. Pre-vaccination Serological Results by ELISA of 9-week-old SPF Chickens to Confirm Negative Serological Status Prior to Vaccination with Water-administered CIAV Vaccine.

Bird No.	Band No.	S/N Ratio by ELISA	CIAV Serological Status
1	104	0.89	Negative ^a
2	108	0.90	Negative
3	128	1.00	Negative
4	133	0.95	Negative
5	141	0.98	Negative
6	190	0.84	Negative
7	191	0.95	Negative
8	201	0.89	Negative
9	215	1.00	Negative
10	217	0.85	Negative
11	742	0.91	Negative
12	747	0.89	Negative
13	753	0.82	Negative
14	765	0.91	Negative
15	768	0.82	Negative
16	826	0.97	Negative
17	838	0.89	Negative
18	850	0.91	Negative
19	856	0.86	Negative
20	866	0.98	Negative

- 15 ^a Negative = S/N Ratio > 0.6 (IDEXX Kit interpretation)

	Hematocrit Values		Clinical Signs	Gross Lesion Scores			
Bird No.	14 dpc ^a	21 dpc	Morbidity/ Mortality	Liver	Bone Marrow	Thymus	Muscle
7	33	33	N/N	0	0	0	0
8	37	NS	N/N	0	0	0	0
9	27	30	N/N	0	0	0	0
10	28	32	N/N	0	0	0	0
11	34	27	N/N	0	0	0	0
12	31	40	N/N	0	0	0	0
13	34	26	N/N	0	0	0	0
14	26	26	N/N	0	0	0	0
15	28	31	N/N	0	0	0	0
16	32	33	N/N	0	0	0	0
17	35	34	N/N	0	0	0	0
18	32	29	N/N	0	0	0	0
19	35	32	N/N	0	0	0	0
20	NS	34	N/N	0	0	0	0
21	35	33	N/N	0	0	0	0
22	28	23	N/N	0	0	0	0

Table 2 Continued on next page

Bird No.	Hematocrit Values		Clinical Signs	Gross Lesion Scores			
	14 dpc ^a	21 dpc	Morbidity/ Mortality	Liver	Bone Marrow	Thymus	Muscle
23	33	38	N/N	0	0	0	0
24	NS	27	N/N	0	0	0	0
25	31	NS	N/N	0	0	0	0
No. Positive	0/21	1/22	0/24 / 0/24	0/24	0/24	0/24	0/24

^a Days post challenge^b No sample^c N= negative^d 0= normal, 1= slight, 2= moderate, 3= severe gross lesions associated with CIA

SUBSTITUTE SHEET (RULE 26)

5 **Table 3. Study 1 Hematocrit Values, Clinical Signs, Mortality and CIA Gross Lesion Scores of Chicks from 27-week-old Non-vaccinated Breeder Chickens Challenged at Day of Age with CIAV (Positive Controls).**

Bird No.	Hematocrit Values		Clinical Signs	Gross Lesion Scores			
	14 dpc ^a	21 dpc		Liver	Bone Marrow	Thymus	Muscle
1	16 ^b	ND ^c	N ^d /P ^e	1 ^f	3	3	2
2	12	ND	N/P	0	3	3	0
3	25	20	N/N	0	0	1	0
4	30	17	N/N	0	2	0	0
5	18	6	P/N	1	3	3	1
6	10	ND	N/P	0	3	3	2
7	28	13	P/N	1	2	2	0
8	33	24	N/N	0	2	2	0
9	22	ND	N/P	0	3	3	0
10	25	10	N/N	0	2	3	1
11	27	32	N/N	0	0	0	0
12	30	13	N/N	0	2	3	0
13	NS ^g	15	N/N	0	3	1	0
14	20	29	N/N	0	0	0	0
15	17	ND	N/P	0	3	3	0
16	16	30	N/N	0	0	0	0
17	25	11	P/N	0	3	3	2
18	23	25	N/N	0	1	1	0
19	33	15	N/N	0	2	2	0
20	15	ND	N/P	0	2	2	0
21	29	16	N/N	0	2	2	0

10 Table 3 continued on next page

5

Bird No.	Hematocrit Values		Clinical Signs / Mortality	Gross Lesion Scores			
	14 dpc ^a	21 dpc		Liver	Bone Marrow	Thymus	
22	25	31	N/N	0	0	0	0
23	23	13	P/N	2	3	3	2
24	44	20	N/N	0	2	1	0
25	25	21	N/N	0	0	2	0
26	35	23	N/N	0	0	1	0
27	12	20	N/N	0	2	2	1
28	30	24	N/N	0	0	0	0
29	33	18	N/N	0	2	2	0
30	25	39	N/N	0	0	0	0
31	25	ND	P/P	0	2	2	1
32	22	ND	N/P	0	1	2	0
33	26	ND	N/P	0	3	3	0
34	20	25	N/N	0	1	1	0
35	17	15	N/N	0	1	2	0
36	33	28	N/N	0	0	0	0
37	31	15	N/N	0	2	2	0
38	25	ND	N/P	0	0	2	0
39	NS	27	N/N	0	0	1	0
40	30	24	N/N	0	1	0	0
No. Positive	23/38	23/30	5/40 / 10/40	4/40	28/40	31/40	8/40
No. Birds with CIA Positive Hematocrit Values ^b /Total=36/40 (90.0%)		No. Dead or Morbid = 14/40 (35.0%)		No. Birds with CIA Gross Lesion Scores ≥1/ Total=33/40 (82.5%)		No. Birds Positive for CIA/Total=38/40 (95.0%)	

^a Days post challenge^b Hematocrit values ≤25=anemia^c Not Done^d N = negative^e P = positive for clinical signs or CIAV mortality^f 0=normal, 1=slight, 2=moderate, 3=severe gross lesions associated with CIA^g No sample

10

Table 4. Study 1 Hematocrit Values, Clinical Signs, Mortality and CIA Gross Lesion Scores of Chicks with Maternal Antibody from 27-Week-old CIAV Vaccinated Breeder Chickens Challenged at Day of Age with CIAV.

Bird No.	Hematocrit Values		Clinical Signs	Gross Lesion Scores			
	14dpc ^a	21dpc		Liver	Bone Marrow	Thymus	Muscle
1	23 ^b	32	N ^c /N	0	0	0	0
5	ND ^d	ND	N/Q ^e	0	0	0	0
6	38	27	N/N	0	0	0	0
7	33	28	N/N	0	0	0	0
9	29	30	N/N	0	0	0	0
10	29	30	N/N	0	0	0	0
11	30	30	N/N	0	0	0	0
12	29	29	N/N	0	0	0	0

Table 4 continued on next page

Bird No.	Hematocrit Values		Clinical Signs	Gross Lesion Scores			
	14dpc ^a	21dpc		Liver	Bone Marrow	Thymus	Muscle
13	27	39	N/N	0	0	0	0
14	34	34	N/N	0	0	0	0
19	28	26	N/N	0	0	0	0
20	31	39	N/N	0	0	0	0
21	30	NS ^f	N/N	0	2 ^g	2	0
23	34	34	N/N	0	0	0	0
24	35	28	N/N	0	0	0	0
25	30	26	N/N	0	0	0	0
28	30	27	N/N	0	0	0	0
29	29	28	N/N	0	0	0	0
30	35	35	N/N	0	0	0	0
33	32	33	N/N	0	0	0	0
34	27	35	N/N	0	0	0	0

Table 4 continued on next page

	Hematocrit Values		Clinical Signs	Gross Lesion Scores			
Bird No.	14dpc ^a	21dpc	Morbidity/ Mortality	Liver	Bone Marrow	Thymus	Muscle
35	23	24	N/N	0	2	2	0
38	16	NS	N/P ^b	0	3	2	2
39	15	33	N/N	0	0	0	0
40	27	35	N/N	0	0	0	0
No. Positive	4/24	1/22	0/25 2/25	0/25	3/25	3/25	1/25
No. Birds with CIA Positive Hematocrit Values ^b /Total=4/24 (16.7%)			No. Dead or Morbid 2/25 (8.0%)	No. Birds with CIA Gross Lesion Scores ≥1/ Total=3/25 (12.0%)		No. Birds CIA Positive/Total= 5/25 (20.0%)	

^a Days post challenge

^b Hematocrit values ≤25=anemia

^c N = negative

^d Not done

^e Q = non CIAV associated mortality

^f No serum

^g 0=normal, 1=slight, 2=moderate, 3=severe gross lesions associated with CIA

^h P=positive for clinical signs or CIAV mortality

Table 5. Study 1 Summary of Hematocrit Values of CIAV Challenged Chicks from 27-Week-old Vaccinated and Non-vaccinated Breeder Chickens.

Group	No. Birds with Hematocrit ≤ 25 at 14 dpc/Total No. Evaluated	No. Birds with Hematocrit ≤ 25 at 21 dpc/Total No. Evaluated	No. Birds with Hematocrit ≤ 25 at either 14 or 21 dpc/Total No. Evaluated
Negative Control	0/21	1/22 (4.5%)	1/24 (4.2%)
Positive Control	23/38 (60.5%)	23/30 (76.7%)	36/40 (90.0%)
Progeny from CIAV Vaccinated Hens	4/24 (16.7%)	1/22 (4.5%)	4/24 (16.7%)
Fisher's Exact Test p=	<0.001 ^a	<0.001 ^a	<0.001 ^a

^a Statistical difference by Fisher's Exact Test at $p < 0.001$ between positive controls and progeny from CIAV vaccinated breeder chickens.

Table 6. Study 1 Summary of Clinical Signs and Mortality of CIAV Challenged Chicks from 27 Week-old Vaccinated and Non-vaccinated Breeder Chickens.

Group	No. with Clinical Signs/Total	No. Dead/Total	No. with Clinical Signs or Dead/Total
Negative Control	0/24	0/24	0/24
Positive Control	5/40 (12.5%)	10/40 (25.0%)	14/40 (35.0%)
Progeny from CIAV Vaccinated Hens	0/25	2/25 (8.0%)	2/25 (8.0%)
Fisher's Exact Test p=	0.08	0.08	0.012 ^a

^a Statistical difference by Fisher's Exact Test at $p < 0.05$ between positive control group and progeny from CIAV vaccinated breeder chickens.

Table 7. Study 1 Summary of CIA Gross Lesion Scores of CIAV Challenged Progeny from 27-Week-old CIAV Vaccinated and Non-vaccinated Breeder Chickens.

Group	No. Birds with Gross Lesion Scores ≥ 1 (GLS)/ Total No. Birds at Post-mortem				No. Birds with GLS ≥ 1 / Total
	Liver	Bone Marrow	Thymus	Muscle	
Negative Control	0/24	0/24	0/24	0/24	0/24
Positive Control	4/40 (10.0%)	28/40 (70.0%)	31/40 (77.5%)	8/40 (20.0%)	33/40 (82.5%)
Progeny from CIAV Vaccinated Hens	0/25	3/25 (12.0%)	3/25 (12.0%)	1/25 (4.0%)	3/25 (12.0%)
Mann-Whitney Test p=	0.5	$<0.001^a$	$<0.001^a$	0.29	$<0.001^a$
Fisher's Exact Test p=	NA ^b	NA	NA	NA	$<0.001^c$

^a Statistical difference at $p < 0.001$ between positive control group and progeny from CIAV vaccinated hens by Mann-Whitney Test.

^b Not applicable.

^c Statistical difference at $p < 0.001$ between positive control group and progeny from CIAV vaccinated hens by Fisher's Exact Test.

Table 8. Study 2 Hematocrit Values, Clinical Signs, Mortality and CIA Gross Lesion Scores of Non-challenged Chicks from 37-Week-old Non-Vaccinated Breeder Chickens (Negative Controls).

Bird No.	Hematocrit Values		Clinical Signs	Gross Lesion Scores			
	14 dpc ^a	21 dpc		Liver	Bone Marrow	Thymus	Muscle
1	31	34	N/N ^b	0 ^c	0	0	0
2	35	33	N/N	0	0	0	0
3	35	37	N/N	0	0	0	0
4	NS ^d	35	N/N	0	0	0	0
5	35	34	N/N	0	0	0	0
6	34	33	N/N	0	0	0	0
7	34	31	N/N	0	0	0	0
8	33	34	N/N	0	0	0	0
9	35	35	N/N	0	0	0	0
10	38	33	N/N	0	0	0	0
11	37	NS	N/N	0	0	0	0
12	34	NS	N/N	0	0	0	0
13	36	35	N/N	0	0	0	0
14	38	33	N/N	0	0	0	0
15	36	NS	N/N	0	0	0	0
16	NS	35	N/N	0	0	0	0
17	35	NS	N/N	0	0	0	0
18	33	35	N/N	0	0	0	0
19	42	38	N/N	0	0	0	0
20	32	35	N/N	0	0	0	0
21	35	37	N/N	0	0	0	0
22	30	31	N/N	0	0	0	0
23	35	34	N/N	0	0	0	0
24	33	35	N/N	0	0	0	0
25	34	34	N/N	0	0	0	0
No positive	0/23	0/21	0/25 / 0/25	0/25	0/25	0/25	0/25

^a Days post challenge

^b N= negative

^c 0=normal, 1=slight, 2=moderate, 3=severe gross lesions associated with CIA

^d No sample

Table 9. Study 2 Hematocrit Values, Clinical Signs, Mortality and CIA Gross Lesion Scores of Chicks from 37-Week-old Non-Vaccinated Breeder Chickens Challenged at Day of Age with CIAV (Positive Controls):

Bird No.	Hematocrit Values		Clinical Signs	Gross Lesion Scores			
	14 dpc ^a	21 dpc		Liver	Bone Marrow	Thymus	Muscle
1	30	20	N/N ^b	0	0	0	0
2	25 ^c	33	N/N	0	0	0	0
3	NS ^d	30	N/N	0	0	0	0
4	29	ND ^e	N/P ^f	0	3 ^g	3	0
5	19	12	N/N	0	2	1	0
6	29	23	N/N	0	2	2	0
7	27	15	N/N	0	3	2	0
8	14	13	N/N	0	0	3	0
9	18	ND	N/P	0	3	3	0
10	25	20	N/N	0	1	0	0
11	33	22	N/N	0	0	0	0
12	21	ND	P/P	0	3	3	0
13	13	23	P/N	0	2	0	0
14	27	23	N/N	0	0	2	0
15	20	ND	N/P	0	3	3	0
16	22	ND	N/P	0	2	3	0
17	24	ND	N/P	0	3	2	0
18	20	23	P/N	0	1	2	0
19	14	ND	N/P	0	3	3	0
20	24	18	P/N	0	2	3	0
21	8	ND	P/P	0	3	3	0
22	15	16	N/N	0	3	3	0
23	24	30	N/N	0	0	0	0
24	27	ND	N/P	0	3	3	0
25	27	29	N/N	0	0	0	0
26	14	15	N/N	0	2	3	0
27	23	ND	N/P	0	3	3	0
28	13	32	N/N	0	0	0	0
29	25	31	N/N	0	0	0	0
30	22	28	N/N	0	0	0	0
31	NS	ND	N/P	0	2	3	0

Table 9 continued on next page

Bird No.	Hematocrit Values		Clinical Signs Morbidity/ Mortality	Gross Lesion Scores			
	14 dpc ^a	21 dpc		Liver	Bone Marrow	Thymus	Muscle
32	35	30	N/N	0	0	0	0
33	24	22	P/N	0	1	2	0
34	17	26	N/N	0	0	0	0
35	29	29	N/N	0	0	0	0
36	25	18	N/N	0	0	0	0
37	27	35	N/N	0	0	0	0
38	23	30	N/N	0	0	0	0
39	20	28	N/N	0	0	0	0
40	18	ND	N/P	0	3	3	0
No. Positive	27/38	15/28	6/40 / 12/40	0/40	22/40	22/40	0/40
No. Birds with CIA Positive Hematocrit Values ^c /Total=32/39 (82.1%)			No. Dead or Morbid=16/40 (40.0%)	No. Birds with CIA Gross Lesion Scores \geq 1/Total=24/40 (60.0%)		No. Birds Positive for CIA/Total=35/40 (87.5%)	

^a Days post challenge^b N= negative^c Hematocrit values \leq 25=anemia^d No sample^e Not Done^f P= positive for clinical signs or CIAV mortality^g 0=normal, 1=slight, 2=moderate, 3=severe gross lesions associated with CIA

Table 10. Study 2 Hematocrit Values, Clinical Signs, Mortality and CIA Gross Lesion Scores of Chicks with Maternal Antibody from 37-Week-old CIAV Vaccinated Breeder Chickens Challenged at Day of Age with CIAV.

Bird No.	Hematocrit Values		Clinical Signs	Gross Lesion Scores			
	14 dpc ^a	21 dpc		Liver	Bone Marrow	Thymus	Muscle
1	30	NS ^b	N/N ^c	0	0	0	0
2	31	33	N/N	0	0	0	0
3	27	36	N/N	0	0	0	0
4	30	36	N/N	0	0	0	0
5	33	ND ^d	N/P ^e	0	2 ^f	3	0
6	30	40	N/N	0	0	0	0
7	27	40	N/N	0	0	0	0
8	29	40	N/N	0	0	0	0
9	30	32	N/N	0	0	0	0
10	28	20 ^g	N/N	0	0	0	0
11	27	34	N/N	0	0	0	0
12	38	39	N/N	0	0	0	0
13	NS	38	N/N	0	0	2	0
14	20	41	N/N	0	0	0	0
15	21	43	N/N	0	0	0	0
16	35	40	N/N	0	0	0	0
17	31	32	N/N	0	0	0	0
18	29	39	N/N	0	0	0	0
19	35	46	N/N	0	0	0	0
20	23	38	N/N	0	0	0	0
21	30	NS	N/N	0	0	0	0
22	26	38	N/N	0	0	0	0

Table 10 continued on next page

Bird No.	Hematocrit Values		Clinical Signs Morbidity/ Mortality	Gross Lesion Scores			
	14 dpc ^a	21 dpc		Liver	Bone Marrow	Thymus	Muscle
23	NS	40	N/N	0	0	0	0
24	33	43	N/N	0	0	0	0
25	42	38	N/N	0	0	0	0
26	30	32	N/N	0	0	0	0
27	30	40	N/N	0	0	0	0
28	25	44	N/N	0	0	0	0
29	27	41	N/N	0	0	0	0
30	33	35	N/N	0	0	0	0
31	36	43	N/N	0	0	0	0
32	30	41	N/N	0	0	0	0
33	32	38	N/N	0	0	0	0
34	ND	ND	N/Q ^b	0	0	0	0
35	30	30	N/N	0	0	0	0
36	31	41	N/N	0	0	0	0
37	42	35	N/N	0	0	1	0
38	34	36	N/N	0	0	0	0
39	27	35	N/N	0	0	0	0
40	ND	ND	N/Q ^b	0	0	0	0
No. positive	4/36	1/35	0/40 /3/40	0/40	1/40	3/40	0/40
No. Birds with CIA Positive Hematocrit Values ^e /Total=5/38 (13.2%)		No. Dead or Morbid 3/40 (7.5%)		No. Birds with CIA Gross Lesion Scores ≥ 1/ Total=3/40 (7.5%)		No. Birds CIA Positive/Total = 8/40 (20.0%)	

^a Days post challenge^b No serum^c N= negative^d Not done^e P= positive for clinical signs and CIAV mortality^f 0=normal, 1=slight, 2=moderate, 3=severe gross lesions associated with CIA^g Hematocrit values ≤25=anemia^h Q= non CIAV associated mortality

5

Table 11. Study 2 Summary of Hematocrit Values of CIAV Challenged Chicks from 37-week-old Vaccinated and Non-vaccinated Breeder Chickens.

Group	No. Birds with Hematocrit ≤ 25 at 14 dpc/Total No. Evaluated	No. Birds with Hematocrit ≤ 25 at 21 dpc/Total No. Evaluated	No. Birds with Hematocrit ≤ 25 at either 14 or 21 dpc/Total No. Evaluated
Negative Control	0/23	0/21	0/25
Positive Control	27/38 (71.1%)	15/28 (53.6%)	32/39 (82.1%)
Progeny from CIAV Vaccinated Hens	4/36 (11.1%)	1/35 (2.9%)	5/38 (13.2%)
Fisher's Exact Test p=	<0.001 ^a	<0.001 ^a	<0.001 ^a

^a Statistical difference by Fisher's Exact Test at $p < 0.001$ between positive controls and progeny from CIAV vaccinated breeder chickens.

10

5

Table 12. Study 2 Summary of Clinical Signs and Mortality of CIAV Challenged Chicks from 37-week-old Vaccinated and Non-vaccinated Breeder Chickens.

Group	No. with Clinical Signs/Total	No. Dead/Total	No. with Clinical Signs or Dead/Total
Negative Control	0/25	0/25	0/25
Positive Control	6/40 (15%)	12/40 (30%)	16/40 (40.0%)
Progeny from CIAV Vaccinated Hens	0/40	3/40 (7.5%)	3/40 (7.5%)
Fisher's Exact Test p=	0.013 ^a	0.010 ^a	<0.001 ^a

^a Statistical difference by Fisher's Exact Test at $p < 0.05$ between positive control group and progeny from CIAV vaccinated breeder chickens.

10

5 Table 13. Study 2 Summary of CIA Gross Lesion Scores of CIAV Challenged Progeny from 37-Week-old CIAV Vaccinated and Non-vaccinated Breeder Chickens.

Group	No. Birds with Gross Lesion Scores (GLS) ≥ 1 / Total No. Birds at Post-mortem				No. Birds with GLS ≥ 1 / Total
	Liver	Bone Marrow	Thymus	Muscle	
Negative Control	0/25	0/25	0/25	0/25	0/25
Positive Control	0/40	22/40 (55%)	22/40 (55%)	0/40	24/40 (60%)
Progeny from CIAV Vaccinated Hens	0/40	1/40 (2.5%)	3/40 (7.5%)	0/40	3/40 (7.5%)
Mann-Whitney Test p=	0.500	<0.001 ^a	<0.001 ^a	0.293	<0.001 ^a
Fisher's Exact Test p=	NA ^b	NA	NA	NA	<0.001 ^c

10 ^a Statistical difference at $p < 0.001$ between positive control group and progeny from CIAV vaccinated hens by Mann-Whitney Test.

^b Not applicable.

15 ^c Statistical difference at $p < 0.001$ between positive control group and progeny from CIAV vaccinated hens by Fisher's Exact Test.

5

EXAMPLE 8**EVALUATION OF TUMORIGENICITY IN CHICKENS FOLLOWING
VARIOUS TREATMENTS ON MDCC-MSB-1 CELLS TO INACTIVATE
MAREK'S VIRUS**

10

INTRODUCTION

A tumorigenicity study was conducted on the MDCC-MSB-1 cell line substrate used for propagation of the Del-Ros strain of CIAV. The objective of this study was to demonstrate that a cell-free supernatant fluid derived from actively growing cell cultures lack the ability to induce Marek's Disease (MD) tumors when inoculated into susceptible chickens.

15

MATERIALS AND METHODS

20

Groups of 25 to 36, SPF white leghorns chicks, aged 1-5 days were inoculated with various inocula as shown in Table 1.

25

Chicks of both trials were observed daily for clinical signs of MD, and the dead birds were necropsied and examined for gross lesions of MD during a 8 week observation period. At the end of the observation period, all of the remaining birds (including the negative controls) were sacrificed with CO₂ and examined for MD related gross lesions. Samples of questionable or suspicious lesions were collected in 10% formaldehyde solution for histopathological examination.

30

RESULTS

The MSB-1 cells without an additional processing step at a dose of 1×10^6

- 5 viable cells induced tumors in 2 of 36 chickens. However, additionally processed
cell free media did not induce tumors in chickens. The results are summarized in
Table 2.

SUMMARY

10

The data obtained from this study indicate that if MSB-1 cells are used as the
substrate for virus production such as for CIAV, it is necessary to remove MSB-1
cells from the harvested virus to prevent the potential of Marek's disease in chickens
receiving the CIAV vaccine. Removal of the cells can be accomplished by filtering
15 the MSB-1 virus infected cells through a coarse filter (5 u size Millipore) to remove
the cells. The cell-free virus fluid would be safe for to administer to chickens.

The results of this study demonstrated that additional processing steps of the
live virus (i.e., natural sedimentation followed by filtration through 5u Millipore
filter) of the MSB-1 cells eliminates the possibility of a vaccine produced in this cell
20 line from inducing any MD related tumors in chickens.

The results suggest that filtration of the supernatant fluid of chicken anemia
virus produced in MSB-1 cells will prevent the associated risk of MD tumor
formation when administered to chickens.

Table 1 Experimental design for the MSB-1 in-vivo tumorigenicity test:

Group No.	Treatments	Total no. of chicks	Route of Inoculation	Dose of Inoculum/ Chick
1.	1.0×10^6 viable MSB-1 cells grown in RPMI 1640 medium supplemented with FBS.	36	SQ ^a	0.2ml
2.	Supernatant from a centrifuged (2000 rpm for 10 min.) MSB-1 cell suspension.	35	SQ	0.2ml
3.	RPMI 1640 medium supplemented with FBS (Medium control).	25	SQ	0.2ml
4.	3.0×10^5 viable MSB-1 cells/ml, allowed to sediment naturally for overnight and the resulting supernatant then filtered through 5u Millipore filter, and finally treated at 41°C for 24 hours before used for chick inoculation.	35	SQ	0.2ml
5.	3.0×10^5 viable MSB-1 cells/ml, allowed to sediment naturally for overnight and the resulting supernatant then filtered through 5u Millipore filter before using for chick inoculation.	35	SQ	0.2ml
6.	3.0×10^5 viable cells/ml, freeze and thawed 3 times at -20°C and then centrifuged at 2000 rpm for 15 min., the resulting supernatant then filtered through 5u Millipore filter, and lastly the filtrate was exposed to 41°C for 24 hours before using for chick inoculation.	35	SQ	0.2ml
7. ---	Negative controls	35	ND	ND

^aSubcutaneous

Table 2. Tumorigenicity test results of MDCC-MSB-1 cells.

Test groups	Total mortality	Necropsy results (MD related lesions)		Total Pos. For MD lesion	% MD Pos.	Remarks
		Gross	Histopath			
1	2/36	7	4	11	30.5	1x10 ⁶ viable cells/chick indicates risk of MD tumor formation
2	0/35	2	3	5	14.3	Centrifuging at 2000 rpm for 15 min. is not enough to eliminate cells from the cell suspension, resulting in low incidence of tumor formation.
3	0/25	0	ND	0	0.0	The medium used for growing MSB-1 cells is safe for use
4	1/35	0	ND	0	0.0	Cell free filtrate does not induce tumor; safe for use in vaccine production
5	0/35	0	ND	0	0.0	Cell free filtrate does not induce tumor; safe for use in vaccine production
6	0/35	0	ND	0	0.0	Cell free filtrate does not induce tumor; safe for use in vaccine production
7	0/35	0	ND	0	0.0	No tumors in the negative controls

5

EXAMPLE 9**THE EFFECTS OF FREEZE-THAW AND 37°C INCUBATION ON THE
VIABILITY OF MAREK'S DISEASE VIRUS**

10

SUMMARY

Freeze-thaw up to 3 cycles could not completely inactivate Marek's disease virus (MDV) in tissue culture medium, but reduced the number of plaques significantly. However, following 3 freeze-thaws and then 3 days' incubation at 37°C, there was no MDV serotype 1 virus detected by IFA.

15

INTRODUCTION

20

Marek's disease virus and turkey herpesvirus (HVT) exist in either cell-associated or cell free states, which have greatly different survival properties. The infectivity of cell-associated virus stock is directly related to viability of the cells containing the virus. The infectivity of cell free virus preparation was reported to be sensitive to different pH and temperatures. The viability of MDV, Rispen's strain, under freeze-thaw and 37°C incubation treatments was investigated.

25

MATERIALS and METHODS

30

1. Cells: The CEF cells (primary CEF in roller bottle, secondary CEF in 60mm tissue culture plates) were prepared from 9 to 11 days-old SPF chicken embryos (SPAFAS).

- 5 2. Virus: The effect of freeze-thaw on the viability of Rispen's virus was investigated by conducting an inactivation (kill) study. The active Rispen's infected CEF cells were harvested at 43 hpi. The infected cells were resuspended in minimal essential medium (MEM) supplemented with fetal and calf sera and tryptose phosphate broth, and filled into 20 tubes. The concentration of the cells was 36×10^6 cells per ml. Samples were treated by freezing at -70°C followed by thawing at room temperature, from one up to three cycles, then incubated at 37°C , from one up to 15 days. The samples, with or without dilution, were inoculated into secondary CEF monolayer in 60mm tissue culture plates in duplicate, and incubated at 37°C for 4-5 days. Titers were scored by count plaques under a microscope with and without IFA stain with MDV serotype 1-specific monoclonal antibody 2BN90.

RESULTS and DISCUSSION

- 20 The MDV plaques were counted and reported as the average plaque forming unit (pfu) per ml. The results indicated that up to 3 freeze-thaw cycles did not completely inactivate MDV Rispen's strain in tissue culture medium, but the number of plaques that indicated evidence of viable virus were reduced significantly. However, with 3 or more days incubation at 37°C after 3 freeze-thaw cycles, there were no plaques detected by IFA (Table 1, and Figures 3 and 4), suggesting that combining 3 freeze-thaw cycles with a 3-day incubation at 37°C can completely destroy MDV infectivity in the cell free medium.

5

Table 1. The average MDV plaques resulting following each treatment

Treatment	Results
<u>Initial titer prior to freeze-thaw:</u>	<u>5.4×10^6 pfu/ml</u>
Freeze-thaw once:	3×10^4 pfu/ml
10 Freeze-thaw twice:	3×10^3 pfu/ml (By IFA)
Freeze-thaw 3 times:	<u>800 pfu/ml (By IFA)</u>
Freeze-thaw 3 times + 37°C 1 day:	70 pfu/ml (By IFA)
Freeze-thaw 3 times + 37°C 2 day:	25 pfu/ml (By IFA)
Freeze-thaw 3 times + 37°C 3 day:	0
15 Freeze-thaw 3 times + 37°C 4 day:	0
Freeze-thaw 3 times + 37°C 5 day:	0
Freeze-thaw 3 times + 37°C 7 day:	0
Freeze-thaw 3 times + 37°C 9 day:	0
Freeze-thaw 3 times + 37°C 11 day:	0
20 Freeze-thaw 3 times + 37°C 13 day:	0
Freeze-thaw 3 times + 37°C 15 day:	0

5

EXAMPLE 10**COMPARISON OF SEQUENCES FOR CIAV STRAINS**

- 10 There are numerous reported strains of CIAV. Some of these have been sequenced and their sequences deposited. A chart comparing the amino acid sequence of several of the known strains is provided below. It is based on a pile up of sequences obtained from the NCBI database.

ATTORNEY DOCKET NO. 02108.0002P1

Specific Amino Acid Changes in VP1, VP2 and VP3 of Several CAV Isolates

Isolate	Identification	VPI Amino Acid Position											
		14	84	92	144	157	229	251	254	287	370	413	447
DRP5	5 th embryo passage Del-Ros strain	A	V	G	E	V	S	R	E	S	G	S	G
DR	Del-Ros strain	A	L	G	E	V	S	R	E	S	G	S	G
TX	Texas Isolate	A	L	G	E	V	F	R	E	T	G	S	T
Cux-1	Cuxhaven-1	S	L	G	D	V	S	Q	G	A	S	A	T
IV	Intervet Vaccine	A	L	D	E	M	S	R	G	T	S	A	T

ATTORNEY DOCKET NO. 02108.0002PI

Isolate	Identification	VP2 Amino Acid Position		VP3 Amino Acid Position					
		153	169	4	23	73	103	116	118
DRP5	5th embryo passage Del-Kos strain	V	D	L	R	V	S	R	C
DR	Del-Ros strain	V	D	L	R	V	S	R	C
TX	Texas Isolate	V	D	L	R	V	S	R	C
Cux-1	Cuxhaven-1	A	D	L	R	V	S	K	R
IV	Intervet Vaccine	V	G	P	Q	A	N	R	C

5

Nucleotide and amino acid sequences for the Del Ros strain are provided in the Sequence listing and also at NCBI accession no. AF313470. Nucleotide and amino acid sequences for additional other strains of CIAV can be found as follows: intervet – NCBI accession no. D100068; Cuxhaven-1 – NCBI accession no.

- 10 NC001427; and CAV-15 – NCBI accession no. AF372658. A nucleotide by nucleotide or amino acid by amino acid comparison of these and other sequence can be routinely made.

Throughout this application, various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by
15 reference into this application in order to more fully describe the state of the art to which this invention pertains.

- It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the scope or spirit of the invention. Other embodiments of the invention will be apparent to those
20 skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims.

25

What is claimed is:

1. A chicken infectious anemia virus (CIAV) vaccine, comprising live CIAV passaged in MDCC-MSB-1 (MSB-1) cells, wherein the vaccine does not cause Marek's Disease.
2. The CIAV vaccine of claim 1, wherein the vaccine does not produce gross lesions in chicken embryos.
3. The CIAV vaccine of claim 1, wherein the vaccine does not produce anemia in chicken embryos.
4. A method of making a CIAV vaccine, comprising culturing CIAV in MSB-1 cells, and removing or killing any Marek's disease virus present in the CIAV-containing MSB-1 cell culture.
5. The method of claim 4, comprising subjecting the CIAV-containing MSB-1 cell culture to at least 3 cycles of freezing and thawing, followed by a step of maintaining the cells for about 3 days at about 37°C..
6. The method of claim 4, comprising the step of filtering the MSB-1 cell culture through a 5 micron filter.
7. The method of claims 5 or 6, wherein the method makes a vaccine that does not cause Marek's disease in chickens immunized with the vaccine.
8. A method of immunizing a chicken against CIAV infection, comprising

administering to the chicken an amount of the CIAV vaccine of claim 1 sufficient to induce an immune response to CIAV.

9. The method of claim 8, wherein the immune response is protective against infection by CIAV.

10. The method of claim 8, wherein the immune response is protective against clinical disease caused by CIAV infection.

11. The method of claim 8, wherein the immune response produces antibodies that are protective against CIAV infection in the progeny of immunized chickens.

12. The method of claim 8, wherein the vaccine is administered to chickens from about 4 to 12 weeks of age.

13. The method of claim 8, wherein the vaccine is administered in drinking water.

14. The method of claim 8, wherein the vaccine is administered by parenterally.

15. The method of claim 14, wherein the vaccine is administered by spray.

16. The method of claim 14, wherein the vaccine is administered by injection.

1/3




FIG. 1

SUBSTITUTE SHEET (RULE 26)

2/3




FIG.2




FIG.4




FIG.3

WO 03/020308

PCT/US02/28551

ATTORNEY DOCKET NO. 02108.0002P

SEQUENCE LISTING

<110> Biomune

Leonard, Joan
Rosenberger, John
Cowen, Barrett

<120> CHICKEN ANEMIA VIRUS VACCINE FROM CELL
LINE

<130> 02108.0002P1

<150> 60/317,239

<151> 2001-09-05

<160> 2

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 2294

<212> DNA

<213> Chicken anemia virus

<400> 1

gcattccgag	tggttactat	tccatcacca	ttctagcctg	tacacagaaa	gtcaagatgg	60
acgaatcgct	cgacttcgct	cgcgattcgt	cgaaggcggg	gggcccggag	ccccccgggtg	120
gccccctcc	aacgagtggg	gcatgtacag	gggggtacgt	catcagtaca	gggggggtacg	180
tcacaaaaag	gcgttcccgt	acaggggggt	acgtcacgcg	tacagggggg	tacgtcacag	240
ccaatcagaa	gctgccacgt	tgcgaaagt	acgtttcgaa	aatgggcggc	gcaagcctct	300
ctatatattg	agcgacata	ccggtcggca	gtaggtatac	gcaaggcggg	ccgggtggat	360
gcacgggaac	acgggacaac	cggccgctgg	gggcagtgaa	tcggcgctta	gccgagaggg	420
gcagcctggg	cccagcggag	ccgcgcaggg	gcaagtaatt	tcaaatgaac	gctctccaag	480
aagatactcc	acccggacca	tcaacgggtg	tcaggccacc	aacaagttca	cggccgttgg	540
aaaccctca	ctgcagagag	atccggattg	gtatcgctgg	aattacaatc	actctatcgc	600
tgtgtggctg	cgcgaaatgt	cgcgctccca	cgctaagatc	tgcaactgcg	gacaattcag	660
aaagcactgg	tttcaagaat	gtgccggact	tgaggaccga	tcaacccaag	cctccctcga	720
agaagcgatc	ctgcgacccc	tccgagtaca	gggtaagcga	gctaaaagaa	agcttgatta	780
ccactactcc	cagccgaccc	cgaaccgcaa	gaagggtgat	aagactgtaa	gatggcaaga	840
cgagctcgca	gaccgagagg	ccgattttac	gccttcagaa	gaggacgggtg	gcaccacctc	900
aagcgacttc	gacgaagata	taaatttcga	catcggagga	gacagcggta	tcgtagacga	960
gcttttagga	aggcctttca	caacccccgc	cccggtagct	atagtgtgag	gctgccgaac	1020
ccccaatcta	ccatgactat	ccgcttccaa	ggagtcattc	ttctcacaga	aggactcatt	1080
ctgcctaaaa	acagcacagc	ggggggctat	gcagaccaca	tgtacggggc	gagagtcgcc	1140
aagatctctg	tgaacctgaa	agagttcctg	ctagcgtcaa	tgaacctgac	atacgtgagc	1200
aaaatcggag	gccccatcgc	cggtgagttg	attgcggacg	ggtctaaatc	acaagccgcg	1260
gagaactggc	ctaattgctg	gctgccgcta	gataataacg	tgccctccgc	gacaccatcg	1320
gcatggtgga	gatgggcctt	aatgatgatg	cagcccacgg	actcttgccg	gttctttaat	1380
caccctaagc	agatgacctt	gcaagacatg	ggtcgcatgt	ttgggggctg	gcacctattc	1440
cgacacattg	aaaccgcgtt	tcagctcctt	gccactaaga	atgagggatc	cttcagcccc	1500
gtggcgagtc	ttctctccca	gggagagtac	ctcacgcgtc	gggacgatgt	taaatacagc	1560
agcgatcacc	agaaccgggtg	gcgaaaaggc	gaacaaccga	tgacgggggg	tattgcttat	1620
gcgaccggga	aaatgagacc	cgacgagcaa	cagtaccctg	ctatgcccc	agaccccccg	1680
atcatcacca	gtactacagc	gcaaggcacg	caagtccgct	gcatgaatag	cacgcaagct	1740
tgggtggctat	gggacacata	tatgagcttt	gcaacactca	cagcactcgg	tgcacaatgg	1800
tcttttctc	cagggcaacg	ttcagtttct	agacggctct	tcaaccacca	caaggcgaga	1860

WO 03/020308

PCT/US02/28551

ATTORNEY DOCKET NO. 02108.0002P

```

ggagccggggg accccaaagg ccagagatgg cacaccctgg tgccgctcgg cacggagacc 1920
atcacccgaca gctacatggg agcacccgca tcagagctgg acacaaattt ctttacgctt 1980
tacgtagcgc aaggtacaaa taagtgcgag cagtacaagt tcggcacagc tacatacgcg 2040
ctaaaggagc cggtaatgaa gagcgattca tgggcagtgg tacgcgtcca gtcgggtctgg 2100
caactgggta acaggcagag accataccca tgggacgtca actggggcaa cagcaccatg 2160
tactggggcg ggcagccctg aaaagggggg gggctaaagc ccccccttga accccccctt 2220
gggggggatt cccccccaga ccccccttt aaatagcact caataaacgc agcaattggc 2280
tttatcgca c aatc 2294

```

<210> 2
 <211> 786
 <212> PRT
 <213> Chicken anemia virus

<400> 2

```

Met Ala Arg Arg Ala Arg Arg Pro Arg Gly Arg Phe Tyr Ala Phe Arg
1      5      10      15
Arg Gly Arg Trp His His Leu Lys Arg Leu Arg Arg Arg Tyr Lys Phe
20     25     30
Arg His Arg Arg Arg Gln Arg Tyr Arg Arg Arg Ala Phe Arg Lys Ala
35     40     45
Phe His Asn Pro Arg Pro Gly Thr Tyr Ser Val Arg Leu Pro Asn Pro
50     55     60
Gln Ser Thr Met Thr Ile Arg Phe Gln Gly Val Ile Phe Leu Thr Glu
65     70     75     80
Gly Leu Ile Leu Pro Lys Asn Ser Thr Ala Gly Gly Tyr Ala Asp His
85     90     95
Met Tyr Gly Ala Arg Val Ala Lys Ile Ser Val Asn Leu Lys Glu Phe
100    105    110
Leu Leu Ala Ser Met Asn Leu Thr Tyr Val Ser Lys Ile Gly Gly Pro
115    120    125
Ile Ala Gly Glu Leu Ile Ala Asp Gly Ser Lys Ser Gln Ala Ala Glu
130    135    140
Asn Trp Pro Asn Cys Trp Leu Pro Leu Asp Asn Asn Val Pro Ser Ala
145    150    155    160
Thr Pro Ser Ala Trp Trp Arg Trp Ala Leu Met Met Met Gln Pro Thr
165    170    175
Asp Ser Cys Arg Phe Phe Asn His Pro Lys Gln Met Thr Leu Gln Asp
180    185    190
Met Gly Arg Met Phe Gly Gly Trp His Leu Phe Arg His Ile Glu Thr
195    200    205
Arg Phe Gln Leu Leu Ala Thr Lys Asn Glu Gly Ser Phe Ser Pro Val
210    215    220
Ala Ser Leu Leu Ser Gln Gly Glu Tyr Leu Thr Arg Arg Asp Asp Val
225    230    235    240
Lys Tyr Ser Ser Asp His Gln Asn Arg Trp Arg Lys Gly Glu Gln Pro
245    250    255
Met Thr Gly Gly Ile Ala Tyr Ala Thr Gly Lys Met Arg Pro Asp Glu
260    265    270
Gln Gln Tyr Pro Ala Met Pro Pro Asp Pro Pro Ile Ile Thr Ser Thr
275    280    285
Thr Ala Gln Gly Thr Gln Val Arg Cys Met Asn Ser Thr Gln Ala Trp
290    295    300
Trp Ser Trp Asp Thr Tyr Met Ser Phe Ala Thr Leu Thr Ala Leu Gly
305    310    315    320
Ala Gln Trp Ser Phe Pro Pro Gly Gln Arg Ser Val Ser Arg Arg Ser
325    330    335
Phe Asn His His Lys Ala Arg Gly Ala Gly Asp Pro Lys Gly Gln Arg
340    345    350

```

WO 03/020308

PCT/US02/28551

ATTORNEY DOCKET NO. 02108.0002P

Trp His Thr Leu Val Pro Leu Gly Thr Glu Thr Ile Thr Asp Ser Tyr
 355 360 365
 Met Gly Ala Pro Ala Ser Glu Leu Asp Thr Asn Phe Phe Thr Leu Tyr
 370 375 380
 Val Ala Gln Gly Thr Asn Lys Ser Gln Gln Tyr Lys Phe Gly Thr Ala
 385 390 395 400
 Thr Tyr Ala Leu Lys Glu Pro Val Met Lys Ser Asp Ser Trp Ala Val
 405 410 415
 Val Arg Val Gln Ser Val Trp Gln Leu Gly Asn Arg Gln Arg Pro Tyr
 420 425 430
 Pro Trp Asp Val Asn Trp Ala Asn Ser Thr Met Tyr Trp Gly Gly Gln
 435 440 445
 Pro Met His Gly Asn Asp Gly Gln Pro Ala Ala Gly Gly Ser Glu Ser
 450 455 460
 Ala Leu Ser Arg Glu Gly Gln Pro Gly Pro Ser Gly Ala Ala Gln Gly
 465 470 475 480
 Gln Val Ile Ser Asn Glu Arg Ser Pro Arg Arg Tyr Ser Thr Arg Thr
 485 490 495
 Ile Asn Gly Val Gln Ala Thr Asn Lys Phe Thr Ala Val Gly Asn Pro
 500 505 510
 Ser Leu Gln Arg Asp Pro Asp Trp Tyr Arg Trp Asn Tyr Asn His Ser
 515 520 525
 Ile Ala Val Trp Leu Arg Glu Cys Ser Arg Ser His Ala Lys Ile Cys
 530 535 540
 Asn Cys Gly Gln Phe Arg Lys His Trp Phe Gln Glu Cys Ala Gly Leu
 545 550 555 560
 Glu Asp Arg Ser Thr Gln Ala Ser Leu Glu Glu Ala Ile Leu Arg Pro
 565 570 575
 Leu Arg Val Gln Gly Lys Arg Ala Lys Arg Lys Leu Asp Tyr His Tyr
 580 585 590
 Ser Gln Pro Thr Pro Asn Arg Lys Lys Val Tyr Lys Thr Val Arg Trp
 595 600 605
 Gln Asp Glu Leu Ala Asp Arg Glu Ala Asp Phe Thr Pro Ser Glu Glu
 610 615 620
 Asp Gly Gly Thr Thr Ser Ser Asp Phe Asp Glu Asp Ile Asn Phe Asp
 625 630 635 640
 Ile Gly Gly Asp Ser Gly Ile Val Asp Glu Leu Leu Gly Arg Pro Phe
 645 650 655
 Thr Thr Pro Ala Pro Val Arg Ile Val Met Asn Ala Leu Gln Glu Asp
 660 665 670
 Thr Pro Pro Gly Pro Ser Thr Val Phe Arg Pro Pro Thr Ser Ser Arg
 675 680 685
 Pro Leu Glu Thr Pro His Cys Arg Glu Ile Arg Ile Gly Ile Ala Gly
 690 695 700
 Ile Thr Ile Thr Leu Ser Leu Cys Gly Cys Ala Asn Ala Arg Ala Pro
 705 710 715 720
 Thr Leu Arg Ser Ala Thr Ala Asp Asn Ser Glu Ser Thr Gly Phe Lys
 725 730 735
 Asn Val Pro Asp Leu Arg Thr Asp Gln Pro Lys Pro Pro Ser Lys Lys
 740 745 750
 Arg Ser Cys Asp Pro Ser Glu Tyr Arg Val Ser Glu Leu Lys Glu Ser
 755 760 765
 Leu Ile Thr Thr Thr Pro Ser Arg Pro Arg Thr Ala Arg Arg Cys Ile
 770 775 780
 Arg Leu
 785

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/28551

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 39/12; C12N 15/34, 7/01, 5/10

US CL : 424/186.1, 204.1, 229.1; 435/69.3, 235.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/186.1, 204.1, 229.1; 435/69.3, 235.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
WEST**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,554,525 A (SONDERMEIJER et al) 10 September 1996 (10.09.1996), see entire document.	1-16
Y	US 5,965,139 A (SCHAT et al) 12 October 1999 (12.10.1999), see entire document.	1-16
Y	US 5,491,073 A (NOTEBORN et al) 13 February 1996 (13.02.1996), see entire document.	1-16

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

09 December 2002 (09.12.2002)

Date of mailing of the international search report

13 JAN 2003

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. 703 305-3230

Authorized officer

Laurie Scheiner

Telephone No. 703 308-0196

Form PCT/ISA/210 (second sheet) (July 1998)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.